CA1337526C - Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents - Google Patents

Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents

Info

Publication number
CA1337526C
CA1337526C CA000607006A CA607006A CA1337526C CA 1337526 C CA1337526 C CA 1337526C CA 000607006 A CA000607006 A CA 000607006A CA 607006 A CA607006 A CA 607006A CA 1337526 C CA1337526 C CA 1337526C
Authority
CA
Canada
Prior art keywords
alkyl
carbons
compound
phenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000607006A
Other languages
French (fr)
Inventor
Chung-Ho Park
Walter Adelman Gregory
Randall Kent Carlson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of CA1337526C publication Critical patent/CA1337526C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Antibacterial arylbenzene oxazolidone pharmaceutical of the following formula:

(I) wherein, for the ?, and mixtures of the d and ? stereoisomers of the compound Ar is an aromatic group selected from the group consisting of , , a diazinyl group optionally substituted with X and Y, a triazinyl group optionally substituted with X and Y, , , , and ;

Z is O, S, or NR5, W is CH or N, or also can be S or O when Z is NR5;
X independently is H, -NO2, -S(O)nRI, tetrazoyl, -S(O)2-N=S(O)pR2R3, -SH, , -COR23, -CONR5R6, , , , R6R5N-(CH2), , -CN, -OR5, halogen, -NR5R6, , , -CR23(OR16)OR17, alkyl of 1 to 8 carbons optionally substituted with one or more halogen atoms, OH, =O other than at alpha position, S(O)nR24, or NR5R6, alkenyl of 2-5 carbons or cycloalkyl of 3-8 carbons;
R1 is C1-C4 alkyl, optionally substituted with one or more halogen atoms, OH, CN, NR5R6 or CO2R8;

C2-C4 alkenyl; -NR9R10; -N3; -NHCR4 ; -NMCR4 ;
-NG2; NR9G-NGM+;
R2 and R3 are independently C1-C2 alkyl or, taken together are -(CH2)q-;
R4 is alkyl of 1-4 carbons, optionally substituted with one or more halogens;
R5 and R6 are independently H, alkyl of 1-8 carbons, cycloalkyl of 3-8 carbons -(CH2)tOR8, - (CH2)tNR11R11a, or -O(CH2)tNR11R11a; or taken together are -(CH2)2O(CH2)2-, -(CH2)tCH(COR4)-, or R7 is -NR5R6, -OR5 or R8 is H or alkyl of 1-4 carbons;
R9 is H, C1-C4 alkyl or C3-C8 cycloalkyl;
R10 is H, C1-C4 alkyl, C2-C4 alkenyl, C3-C4 cycloalkyl, -OR8 or -NR11R11A;
R11 and R11A are independently H or C1-C4 alkyl, or taken together, are -(CH2)t-;
G is Cl, Br or I;
Y independently is H, F, Cl, Br, OR8, alkyl of 1-3 carbons, or NO2;

X and Y taken together (a) when Ar is or to form a fused six-membered carbocyclic ring, or (b) when Ar is to form M is a physiologically acceptable cation;
n is 0, 1 or 2 p is 0 or 1;
q is 3, 4 or 5;
r is 4 or 5;
t is 1, 2 or 3;

B is -NH2, or N3;
R12 is H, C1-C10 alkyl or C3-C8 cycloalkyl;
R13 is H; C1-C4 alkyl optionally substituted with one or more halogen atoms; C2-C4 alkenyl;
C3-C4 cycloalkyl; phenyl, -CH2OR15;
-CH(OR16)OR11;

-CH2S(O)vR14; ; -OR18; -SR14;
-CH2N3;
the aminoalkyl groups derived from .alpha.-amino acids such as glycine, L-alanine, L-cysteine, L-proline, and D-alanine; -NR19R20; or -C(NH2)R21R22;
R14 is C1-C4 alkyl, optionally substituted with one or more halogen atoms;
R15 is H or C1-C4 alkyl, optionally substituted with one or more halogen atoms;
R16 and R17 are independently C1-C4 alkyl or, taken together, are -(CH2)m-;
R18 is C1-C4 alkyl or C7-C11 aralkyl;
R19 and R20 are independently H or C1-C2 alkyl;-R21 and R22 are independently H, C1-C4 alkyl, C3-C6 cycloalkyl, phenyl or, taken together, are -(CH2)s-;
u is 1 or 2;
v is 0, 1 or 2;
m is 2 or 3;
s is 2, 3, 4 or 5;
R23 is H, alkyl of 1-8 carbons optionally substituted with one or more halogens, cycloalkyl of 3-8 carbons, alkyl of 1-4 carbons substituted with one or more of - S (O)nR24, -OR8 , or -NR5R6; or alkenyl of 2-5 carbons optionally substituted with CHO or CO2R8;
R24 is alkyl of 1-4 carbons or cycloalkyl of 3-8 carbons; and R25 is R6 or NR5R6;
or a pharmaceutically suitable salt thereof;
provided that: .
1) when B is NH2, then Ar is not phenyl optionally substituted with halogen or CF3.

Description

-` 1 1 33752~
Title AMINOMETHYLOXOOXAZOLIDINYL ARYLBENZENE
DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
Technical Field This invention relates to aminomethyloxooxazolidinyl arylbenzene derivatives, their preparation, to pharmaceutical compositions containing them, and to methods of using them to alleviate bacterial infections.
Background of the Invention At the present time, no existing antibacterial product provides all features deemed advantageous for such a product.
There is continual development of resistance by bacterial strains. A reduction of allergic reactions and of irritation at the site of injection, and greater biological half-life (i.e., longer in vivo activity) are currently desirable features for antibacterial products.
U.S. Patent 4,128,654 issued to Fugitt et al. on December 5, 1978, discloses, among others, compounds of the formula:

~5 A 9 N~

where A = RS ()n;
X = Cl, Br or F;
R = Cl-C3 alkyl; and n = 0, 1 or 2.

The compounds are disclosed as being useful in controlling fungal and bacterial diseases of plants.

~' ~, , .

~ 2 ~ 337526 U.S. Reissue Patent 29,607 reissued April 11, 1978 discloses derivatives of 5-hydroxymethyl-3-substituted-2-oxazolidinones of the formula:

~ ~f R O

where R is H, F CH3, or CF3. Such compounds are described as having antidepressive, tranquilizing, sedative, and antiinflammatory properties.
U.S. Patent 4,250,318, which was issued on February 10, 1981, discloses antidepressant compounds of the formula:

R ~f where R' can be, among others, a E~-n-pentylamino group, an SRl group where Rl is C,-Cs alkyl, or an acetylmethylthio group.
U.S. Patent 4,340,606, issued to Fugitt et al. on July 20, 1982, discloses antibacterial agents of the general formula:

R~S~O)n~3--N~--X

.
.

where Rl = CH3, C2H5, CF2H, CF3 or CF2CF2H; and X = ORi (R2 = H or various acyl moieties).
U.S. Patent 3,687,965, issued to Fauran et al.
on August 29, 1972, discloses compounds of the formula:

. CH2N ( R~ ) ( R2 ) ,~
R3 - N~O

O
where -N(Rl)(R2) represents either dialkylamino radical in which the alkyl portions have one to five carbon atoms, or a heterocyclic amino radical which may be substituted by an alkyl radical having one to five carbon atoms or by a pyrrolidinocarbonylmethyl radical, and R3 represents a phenyl radical which may be substituted by one or more of the following radicals:
an alkoxy radical having one to five carbon atoms;
a halogen atom;
a trifluoromethyl radical, or a carboxyl radical which may . be esterified.
The patent states that these compounds possess hypotensive, 30 vasodilatatory, spasmolytic, sedative, myorelaxant, analgesic and antiinflammatory properties. There is no mention of antibacterial properties.
Belgian Patent 892,270, published August 25, 1982, discloses monoamine oxidase inhibitors of the formula Ar- (X)n~3N O
~f where~
R is H, Cl-c4 alkyl or propargyl;
Ar is phenyl, optionally substituted by halo or trifluoromethyl;
n is 0 or 1; and X is -CH2CH2-, -CH=CH-, an acetylene group or -CH2O-.
U.S. Patent 4,461,773 issued to W.A. Gregory on July 24, 1984 discloses antibacterial agents of the formula ll R1 ~N O

wherein, for the ~, and mixtures of the d and ~ stereoisom~~s of the compound, O NRs Il rl R, is R2SO2, R3R4NC, or R3C
R2 is -NR3R4, -N ( OR3 ) R4, -N3, -NHNH2 /
-NX2, -NR6X, -NXZ, -NHCR" -NZCR7 or O O
-N=S (O) nR8Rg;
R3 and R4 are independently H, alkyl of 1-4 carbons or cycloalkyl of 3-8 carbons;
Rs is NR3R4 or OR3;
R6 is alkyl of 1-4 carbons;
R, iS alkyl of 1-4 carbons, optionally substituted with one or more halogens;
, .

~j r 1~`' R8 and Rg are independently alkyl of 1-4 carbons or, taken together are -(CH2)p-;
o R1o is H, alkyl of 1-3 carbons, -CRl1, o O O \
-C (CH2) mCO2H, -OCH=CHC02H, ~C\2H, ' ' O
C- C

~C02H ~ ~C2 H r - C - CH - R~ 2;

R11 is alkyl of 1-12 carbons;
R12 is H, alkyl of 1-5 carbons, CH2OH or CH2SH;
X is C1, Br or I;
Z is a physiologically acceptable cation;
m is 2 or 3;
n is O or 1; and p is 3, 4 or 5;
and when R1o is alkyl of 1-3 carbons, R1 can . also be CH3S(O)q where q is O, 1 or 2;
or a pharmaceutically acceptable salt thereof.

_ U.S. Patent 4,705,799 issued to Gregory on November 10, 1987 discloses antibacterial agents of the formula:

A ~ N ~ o B

wherein, for the e, and mixtures of the d and e -~ stereoisomers of the compound, A is -NO2, -S(O)nRl, -S(O)2-N=S(O)pR2R3~ -SH, Il 11 ~SCRq~ -COR23, -COR25, -CONR5R6, -C-R23 o o OR8 loRH TCR8 fCR8 .C-R23 -f-R2s 7R23, -C-R25.

-CN, -OR5, halogen, -NR5R6 -NCOR4 IR5 pR5R6 -NS(O)nR4, CR23(ORl6)OR~, -7R23 , alkyl Rg of 1 to 8 carbons, optionally substituted with one or more halogen atoms, OH, =O other than at alpha position, S(O)nR24, NR5R6, alkenyl of 2-5 carbons, alkynyl of 2-5 carbons or cycloalkyl of 3-8 carbons;
Rl is Cl-C4 alkyl, optionally substituted with one or more halogen atoms, OH, CN, NRsR6 or CO2R8; C2-C4 alkenyl; -NRgRlo;

X

`~ 7 1 337526 o o -N3; -NHCR4; -NZCR4; -NX2; NRgX
- -NXZ~; -R2 and R3 are independently Cl-C2 alkyl or, taken together are - (CH2)9-;
R4 is alkyl of 1-4 carbons, optionally substituted with one or more halogens;
Rs and R6 are independently H, alkyl of 1-4 - carbons or cycloalkyl of 3-8 carbons;
O
R, is -NR5R6, -OR5 or NHCR5;
. R8 is H or alkyl of 1-4 carbons; . --Rg is H, Cl-Cs alkyl or C3-C8 cycloalkyl;
Rlo is H, Cl-C4 alkyl, C2-C4 alkenyl, C3-C4 cycloalkyl, -OR8 or -NRIlR~
Rll and R1L'~ are independently H or C1-C4 alkyl, or taken together, are - (CH2)r-;
X is Cl, Br or I;
Y is H, F, Cl, Br, alkyl of 1-3 carbons, or NO2, or A and Y taken together can be -O-( CH2 ) t -;
Z is a physiologically acceptable cation;
n is 0, 1 or 2;
p is O or 1;
q is 3, 4 or 5;
r is 4 or 5;
t is 1, 2 or 3; . ---~R12 ~ R12 B is -NH2, -N C-Rl3, -N-S (O) uRl4 or N3;

8 l 337526 Rl2 is H~ Cl-C10 alkyl or C3~Cg cycloalkyl;
Rl3 is H~ Cl-C4 alkyl optionally substituted with one or more halogen atoms;
C2-C4 alkenyl; c3-C4 cycloalk~-l;-phenyl;

O
-CH ORl5; -CH (ORl6) ORl~; -CH2S (O) "Rl4; CRls;
-Rl8; -SRl4; -CH2N3; the aminoalkyl -groups derived from ~-amino acids such as glycine, L-alanine, L-cysteine,.L-proline, and D-alanine; -NRlgR20; or C(NH2)R2lR22;
Rl4 is Cl-C4 alkyl, optionally substituted with one or more halogen atoms;
Rl5 is H or Cl-C4 alkyl, optionally substituted with one or more halogen atoms;
Rl6 and Rl, are independently Cl-C4 alkyl or, taken together, are -(CH2)m~;
Rl8 is Cl-C4 alkyl or C,-Cll aralkyl;---Rlg and R20 are independently H or Cl-C2 alkyl;
R2l and R22 are independently H~ Cl-C4 alkyl, ~ C3 - C6 cycloalkyl, phenyl or, taken 2 5 together, are -( CH2 ) 8 -;
u is 1 or 2;
v is 0, 1 or 2;
m is 2 or 3;
s is 2, 3, 4 or 5; and R23 is H, alkyl of 1-8 carbons optionally substituted with one or more halogens, or cycloalkyl of 3- 8 carbons;
R24 is alkyl of 1-4 carbons or cycloalkyl of . 3- 8 carbons;
R2s is alkyl of 1-4 carbons substituted with one or more of -S(O)nR24, -OR8, ol -OCR8, -NRsR6, or alkenyl of 2-5 carbons optionally substituted with CHO; or a pharmaceutically suitable salt thereof; provided that:
1) when A is CH3S-, then B is not -N-CO2CH3;
-2) when A is CH3SO2-, then B is not lCH3 ICH3 -N-COCH3 or -N-COCF3;
~R12 3) when A is H2NSO2- and B is -N CRl3, then Rl2 is H;
4) when A is -CN, B is not -N3;
5) when A is (CH3)2CH, B is not NHCOCH2Cl;
6) when A is ORs, then B is not NH2;
7) when A is F, then B is not NHCO2CH3.
None of the above-mentioned references suggest the novel antibacterial compounds of this invention.
Summarv of the Invention According to the present invention, there is provided an arylbenzene oxazolidinone of the formula:

o A r ~3N O
\~B

(I) .~

wherein, for the e and mixtures of the d and stereoisomers of the compound Ar is an aromatic group selected from the group consisting of ~ N~ , d i az i ny I g roup optionally substituted with X and Y, a triazinyl group optionally substituted with X
and Y, Y~,~ y~X y~

2 0 d \~
Rs Z is 0, S, or NRs;
W is CH or N, or also can be S or O when Z is NRs;
X independently is H, -NO2, -S(O)nRl, tetrazoyl, ~"'~L

-S(o)2-N=s(o)pR2R3~ -SH, -SCR4.-COR23 . 5 NR7 loR8 lo~cR8 -coNRsR6~ -C-R23. T-R23~ Cl 23 OR~
R6R5N- (CH2, t -f - . -CN -OR5, halogen, -NR5R6, -NCOR4, -NS()nR4, -CR23(oR16)oR1~ -CR23, alkyl Rg of 1 to 8 carbons optionally substituted with one or more halogen atoms, OH, =O other than at alpha position, S(O)nR24, or NRsR6, alkenyl of 2-5 carbons or cycloalkyl of 3-8 carbons;
R1 is Cl-C4 alkyl, optionally substituted with one or more halogen atoms, OH, CN, NRsR6 or CO2R8;
O O
Il C2-C4 alkenyl; -NRgRlo; -N3; -NHCR4; -NMCR4;
-NG2; NRgG~~NGM~;
R2 and R3 are independently Cl-C2 alkyl or, taken together are -( CH2 ) q-;
R4 is alkyl of 1-4 carbons, optionally substituted with one or more halogens;
Rs and R6 are independently H,- alkyl of 1-8 carbons, cycloalkyl of 3-8 carbons -(CH2)tOR8, -(CH2)tNR1lRlla, or -~CH2)tNRllRlla; or taken together are -( CH2 ) 2 ( CH2 ) 2 -;
- (CH2) tCH (COR4) -, or -( CH2) 2tN (CH~) 2~;

~O
R7 is -NRsR6, -ORs or NHCRs;

R8 iS H or alkyl of 1-4 carbons;
R9 iS H, C1_C4 alkyl or C3_C8 cycloalkyl;
R10 is H, C1-C4 alkyl, C2-C4 alkenyl, C3_C4 cycloalkyl, -OR8 or -NR11R1lA;
R11 and R11A are independently H or C1_CS alkyl, or taken together, are -(CH2) r~;
G is C1, Br or I;
Y independently is H, F, C1, Br, OR8, alkyl of 1-3 carbons, or N2; X
X and Y taken together (a) when Ar is N ~ to form a fused six-membered ~ N
carbocyclic ring, or (b) when Ar is N~

M is a physiologically acceptable cation;
n is 0, 1 or 2;
p is O or 1;
. q is 3, 4 or 5;
r is 4 or 5;
t is 1, 2 or 3;
IRl2 1l ~Rl2 B is -NH2, -N C_R13, -N-S ()UR14, or N3;
R12 is H, C1_C10 alkyl or C3-C8 cycloalkyl;
R13 iS H; C1-C4 alkyl optionally substituted with one or more halogen atoms; C2 - C4 alkenyl;
C3_C4 cycloalkyl; phenyl; -CH20R15;
-CH (R16) R17;

-CH2S (O)~,Rl4; -CRl5; -Rl8; - SRl4;
- CH2N3;

.

- the aminoalkyl groups derived from ~-amino acids such as glycine, L-alanine, L-cysteine, L-proline, and D-alanine; -NRlgR20; or -C (NH2) R2lR22;
Rl4 is Cl-C4 alkyl, optionally substituted with one or more halogen atoms;
Rls is H or Cl-C4 alkyl, optionally substituted with one or more halogen atoms;
Rl6 and Rl7 are independently Cl-C4 alkyl or, taken together, are -(CH~) m~;
Rl8 is Cl-C4 alkyl or C,-Cll aralkyl;
Rlg and R20 are independently H or Cl~C2 alkyl;
R2l and R22 are independently H~ Cl-C4 alkyl, C3-C6 cycloalkyl, phenyl or, taken together, are -( CH2 ) ~ ~;
u is 1 or 2;
v is 0, 1 or 2;
m is 2 or 3;
s is 2, 3, 4 or 5;
R23 is H~ alkyl of 1-8 carbons optionally substituted with one or more halogens, cycloalkyl of 3-8 carbons, alkyl of 1-4 carbons substituted with one or more of -S(O)nR24, ~ORs~
- O
-OCR8, or -NR5R6; or alkenyl of 2-5 carbons optionally substituted with CH0 or CO2R8;
R24 is alkyl of 1-4 carbons or~cycloalkyl of 3-8 carbons; and R2s is R6 or NRsR6;
or a pharmaceutically suitable salt thereof;
provided that:
1) when B is NH2, then Ar is not phenyl optionally substituted with halogen or CF3.

~ 7 When used herein, the term "a diazinyl group optionally substituted with X and Y" means the following groups:

~ ~ ' 3 N~, a n d X

When used herein, the term "a triazinyl group optionally substituted with X and Y" means the - following groups:

N--N X~N _ NN--N

~ N ~X ~ N
X Y

X x r N~ ,~ /)--. and N

, ' _ 15 Also provided is a pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and a compound of Formula (I) and a method of using a compound of Formula (I) to treat bacterial infection in a m~m~
Further provided is a process for preparing compounds of.Formula (I?, such a process being described in detail hereinafter.

Preferred Embodiments 1. Preferred Ar groups are:

~ , N~, o r where X and Y are as defined.
More preferred Ar groups are those preferred Ar groups where Y is H.
Most preferred Ar groups are the preferred Ar groups where Y is H and X is H, alkyl of 1-5 carbon atoms, - SCH3, - SOCH3, - SO2CH3, - 10CH3, ORs, - CH2NR5R6 R6RsN (CH2) 2CH (OH) -, or -CN.

2. A preferred B group is: ~

-NHCR13 where Rl3 is H, CH3, -Rl8~ CH2 CH20H, or CH20CH3.
O O
Preferred B groups are -NHOCH3, -NHCOCH3, and -NHOCH2Cl; and -NHlCH3 iS specifically preferred.

16 l 337526 Specifically preferred compounds are:
( e ) -N-[3-(4-phenylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
( e ) -N-[3-(4-(4'-acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
( e ) -N-[3-(4-(4'-methylsulfinylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
(e) -N-[3-(4-(4'methylsulfonylphenyljphenyl) 2-oxooxazolidin-5-ylmethyl]acetamide;
(e)-N-[3-(4-(4'-cyanophenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
(Q)-N-[3-(4-(4~-diethylaminomethylphenyl)-phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
(e)-N-[3-(4-(4'-di-n-propylaminomethylphenyl)-phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
(Q)-N-[3-(4-(4~-(3-N~N-dimethylamino-l-hydroxypropyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
(e)-N-[3-(4-(4'-(1-hydroxy-3-(4-morpholinyl)-propyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide;
(e)-N-[3-(4-(4'-pyridylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, hydrochloride;
(e)-N-[3-(4-(3'-pyridylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, hydrochloride.

Detailed Description The compounds of Formula (I) contain at least one chiral center, and as such exist as two individual isomers or as a mixture of both. This invention relates to the levorotatory isomer ( e ) which for many of the compounds in this invention can be referred to as the (S) isomer, as well as mixtures containing both the (d) or (R) and (S) isomers. Additional chiral centers may be present in the groups Ar and/or B; and this invention relates to all possible stereoisomers in these groups.
For the purpose of this invention, the e-isomer of compounds of Formula (I) is intended to mean compounds of the configuration depicted; when B is NHAc, and closely related groups, this isomer is described as the (S)-isomer in the Cahn-Ingold-Prelog nomenclature:

o A r ~N O
~
/~, B
(I) Synthesis Compounds of Formula (I) can be prepared as . follows:

X

lB
Sche~ 1 .

U ) ~NCH~ N 1 0 0{~ N o (~ ) (m) I ?
O _ O
~ o ~J" r C~}Il O ~Xl) D

~Dt I

~) .~, o R~ ~

I~IR5R2~ 0 R2~ ~N O

~V) iR5R25 0 Rl) J~}~

2j (Vl) l 337526 Scheme 1 ( Cont inued ) (IV) ~ o R23 ) (XVI) R5R6N ( CH2 ) 2~ ~

(XIII ) 2 5 R5R6N ( CHz ) 2 R~ ~~'=~`N J ~ o (XIV) ocOR8 `~

(XV) Scheme 1 ( Cont inued ) (IV) 1\~
/ oR8 o ~ R23 (XIX) OCOR8 ~

/ R6 ~ ~ _~
(XX) 20.

NoR5 o R23,/~ ~

(XVII) NOCOR

R23"~" /r N B

(XVIII ) In Scheme 1, R23 is H or alkyl of 1-8 carbons optionally substituted with a halogen or a terminal carboxylic acid or its salts. Rs~ R6, and B are as described previously. R8 is H or alkyl of 1-4 carbons optionally substituted with a terminal carboxylic acid or its salts.
The compound (II) is converted to a compound of Formula (III) according to the process exactly paralleling that which was previously described in U.S. Patent 4,705,799. The B groups in Formula (I) can be selected from a variety of groups described and prepared according to the procedures disclosed in the above patent.
A compound of Formula (III) is acylated with acetic anhydride, propionic anhydride, chloroacetic anhydride or succinic anhydride also according to the process described in the aforesaid patent to - give a compound of Formula (IV). Reaction of a compound of Formula (IV) with a substituted hydrazine in a solvent such as ethanol, methanol or THF at 20OC to under refluxing temperature of the solvent chosen gives a hydrazone of Formula (V), which can be reduced to a hydrazine derivative of Formula (VI) by reduction using a borohydride such as sodium cyanoborohydride in methanol at 25O to 550C.
A compound of Formula (III) is iodinated with iodine monochloride in an acetic acid-trifluoroacetic acid mixture at 40 to 70OC to acompound of Formula (VII), which -an be converted to a cyano compound of Formula (VIII) by reaction with cuprous cyanide. The cyano group of a compound of (VIII) can be converted to a tetrazole derivative of Formula (IX) by reaction with trimethylsilyl azide in DMF at 120-145C. An iodocompound (VII) can also be converted to an ~T
1~

aldehyde of Formula (X) by addition of carbon mQ~ox;de in a suitable solvent such as THF, glyme and DMF or mixtures thereof at 400 to 700C in the presence of a catalyst such as tributyltin hydride and tetrakis(triphenylphosphine)palladium(0). An aldehyde of (X) can be converted to the corresponding carboxylic acid of Formula (XI) by oxidation with variety of oxidants such as chromic acid.~ An aldehyde of (X) can also be reductively aminated with an alkylamine such as diethylamine, ethylmethylamine or methylpiperidine in an alcoholic solvent using a reducing agent such as sodium cyanoborohydride and zinc chloride at oo to 350C to give an amine of Formula (XII).
Mannich reaction of a ketone of Formula (IV) with variety of alkylamines previously described gives a Mannich base of Formula (Y.III) which can be reduced to an alcohol of Formula (XIV) with a borohydride reducing agent such as sodium cyanoborohydride in methanol. An alcohol of Formula (XIV) can be converted to a half ester of a dibasic acid of Formula (XV) by treatment with a dibasic acid anhydride such as succinic or glutaric anhydrides. When the Mannich reaction is carried out with a ketone of Formula (IV), where R23 is ethyl, with dimethylamine, an unsaturated ketone of Formula (XVI) is also obtained.
A ketone of Formula (IV), when reacted with an hydroxylamine or a carboxymethyloxyamine in ethanol -in the presence of pyridine, produces the corresponding oxime of Formula (XVII). An oxime of Formula (XVII) can be converted to the oximino half ester of a dibasic carboxylic acid of Formula (XVIII) by reaction with a dibasic acid anhydride such as succinic and glutaric anhydrides.

A ketone or aldehyde of Formulae (IV) and (X) can be reduced to a corresponding alcohol of Formula (XIX) by a reducing agent such as sodim borohydride. An alcohol of Formula (XIX) can be esterified with a mono- or dibasic acid anhydride to give a corresponding ester of Formula (XX).
Scheme 2 R3SnSnR3, Pd (O) ArMgBr or ArLi ~ Ar -M
(XXI) (XXII) (XXIII) o Ar-M ~ 1~ Catalyst ~N O

(XXI I I ) (XXIV) ( I ) 8 or Ar I M~N O Catalyst ~ ~N

As shown in Scheme 2, Ar is as described previously provided that it contains no active hydrogen, (i.e., no NH, OH or SH), M is a zinc chloride, trialkyltin or boronic acid radical and the catalyst can be selected from one of the many palladium or nickel coordination compounds such as bis(triphenylphosphine)palladium(II) chloride, tri(2-tolyl)phosphine and palladium(II) acetate, or bis(triphenylphosphine)nickel(II) chloride. An aromatic bromide of Formula (BI) is converted to a corresponding Grignard reagent with magnesium or to S a lithium reagent with alkyllithium by the usual procedures which are well known in the art. A
reagent of Formula (XXII) is converted to an organozinc chloride compound with zinc chloride, to a trialkyltin compound with trialkyltin chloride or to a-boronic acid with triisopropylborate, each followed by basic hydrolysis in a suitable solvent such as ether, THF or glyme. Alternativelly, when Ar contains active hydrogens, an organotin compound of Formula (XXIII) can be prepared by a palladium catalyzed reaction with a bistrialkyltin reagent.
A resulting organometallic compound of Formula (XXIII) is cross coupled with a 3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl derivative of Formula (XXIV) in a suitable solvent such as THF or DMF in the presence of a catalyst usually selected from those previously described. The cross coupling reaction works equally well when an aryliodide and a 3-(4-trialkylstannylphenyl)-2-oxooxazolidinyl derivative is reacted in the same manner. The iodo compound of Formula (XXIV) is prepared by iodinating (e)-N-(3-phenyl-2-oxooxazolidin-5-ylmethyl)acetamide using iodine and silver trifluoroacetate or iodine monochloride in a solvent such as chloroform, acetonitrile, acetic acid or mixtures of solvents thereof at a temperature of Oo to 600C, followed by normal work-up procedures.
Another coupling reaction, although limited in its applicability, can be used to prepare a compound of Formula (I) where Ar is a dihydroxyphenyl as described in synthetic Scheme 3.

`~ 26 1 337526 Scheme 3 O O O

Q u i n o n e ~ N 2 ~ ~ B ~ N~)~/~, B

(XXV) (XXVI) OH O

~ N o (XXVII) Quinone is reacted with a diazonium salt (B V) prepared from a 3-(4-aminophenyl)-2-oxooxazolidin-5-ylmethyl derivative to give an adduct of Formula (XXVI), which can be reduced wtih a borohydride reducing agent such as sodium borohydride to give a dihydroxy compound of Formula (XXVII). The hydroxy groups can be converted to the corresponding ethers using conventional techniques.
Scheme 4 Ar~COH Ar~cN3 Ar~3N~,B

(XXVIII) (XXIX) (I) Synthetic Scheme 4 is widely applicable to prepare most of the compounds of Formula (I) provided that there are no active hydrogen atoms (i.e., no NH, OH or SH) present in Ar as described previously. Compounds containing these excluded groups can be prepared via Schemes 1, 3 or 5. A
compound of Formula (XXVIII) can be prepared in variety of ways. For example, many of such compounds can be prepared by procedures described in D.J. Byron, G.W. Gray and R.C. Wilson, J.
Chem. Soc. (C), 840 (1966). A compound of Formula (XXVIII) can be converted to the corresponding acid chloride followed by reaction with sodium azide according to standard organic reaction procedures to a compound of Formula (XXIX). A compound of Formula (XXIX) is then employed in place of the compound of Formula (II) in Scheme I to give the compound of Formula (I).

, . , Sche~r~ S

~qNa)-C~ ~ N O

(~5e)2~Me2 o N~O ( ~OCX ) Br2 /CHCl 3 o o ,L~ N ~ O

' ~- o 29 1337526 Scheme 5 ( Cont inued ) ( XXXI ) H2NOSO3H ~ ~ o MeOH

N2H4 EtOH ~ \ B

H

N\/ ~
MeoNB N N--N~ ~N J~--o N2co3MeoH H20 NH2~ 0 3 NH N \> ~\r N B

~ 0 30 l 337526 Scheme S
(Continued) S (XXXII) CH2CSNH2 > <\ ~ r----N O
Toluene.heat N ~ ~ B

EtOH.heat NH2 ~ \N~ \ / r \ _ / B

OHCNH2 ~ < 0 \ ~ B

Compounds of Formula (I) which can be prepared according to the synthetic Scheme 5 are those with Ar groups made up of 5- and 6-membered ring heterocycles as illustrated.
A 3-(4-acetylphenylj-2-oxooxazolidin-5-yl derivative (XXX) prepared according to U.S. Patent 4,705,799 is converted to a compo.lnd of Formula (XXXI) by reacting it with dimethoxydimethyl-formamide at 100 to 120C. Reaction of a compound of Formula (XXXI) with a variety of amines give compounds of Formula (I) where Ar is an heteroaromatic moiety as shown.
Similarly, a bromoacetyl derivative (XXXII) where B is azide (N3) obtained by bromination of a - compound (XXX) can be reacted with a variety of amides to produce more compounds of Formula (I) where Ar is an heteraromatic moiety. Azides can be reduced to amines as described in U.S. 4,705,799.
Pharmaceutically suitable salts of compounds of Formula (I) can be prepared in a number of ways known in the art. When B is NH2, pharmaceutically suitable salts include those resulting from treatment with mineral and organic acids such as acetic, hydrochloric, sulfuric, phosphoric, succinic, fumaric, ascorbic, and glutaric acids.
The invention can be further understood by reference to the following examples in which parts and percentages are by weight~unless otherwise indicated.

f~

~ 32 1 337526 Exam~le 1 Preparation of (e)-5-Azidomethyl-3-(4-phenylphenyl)-2-oxazolidinone (I, Ar=C6Hs, B=N3) Part A: Preparation of (e)-5-Hydroxymethyl-3-(4-phenyl phenyl)-2-oxazolidinone (I, Ar=C6H5, B=OH) A solution containing 10 g (51.2 mmol) of 4-phenylphenylisocyanate and 7.5 g (52.0 mmol) of (e)-glycidyl butyrate in 20 mL of dry xylene was added dropwise to 160 mL of boiling dry xylene containing 0.30 g of lithium bromide and 0.75 g of tributylphosphine oxide over a period of 30 minutes. The mixture was heated under reflux for 1 hour after the addition was complete, allowed to cool to room temperature and the solvent was removed under reduced pressure. The residue was triturated with hexane and the resulting solid was dissolved in 150 mL of methanol. To this solution was added 0.7 mL of 25~ sodium methoxide in methanol, stirred overnight and the white precipitate formed was collected on a filter to give 13 g (95~ theory) of the desired alcohol, mp 236-240OC, shown to be at least 99~ pure by HPLC.
The alcohol can be further purified by recrystallization from methanol.

Part B: Preparation of (e)-5-Hydroxymethyl-3-(4-phenylphenyl)-2-oxazolidinone ~-toluene-sulfonate (I, Ar=C6Hs, B=OTs) To a solution of 12.94 g (48.05 mmol) of ( e ) - 5-hydroxymethyl-3-(4-phenylphenyl)-2-~ 33 l 337526 oxazolidinone in 100 mL of dry pyridine was added 10.6 g (15% excess) of ~-toluenesulfonyl chloride at 0-5C, and the mixture was stirred at 10-15C until all of the alcohol was converted to the tosylate (Ts) as shown by HPLC analysis. The mixture was poured into 500 mL of ice water with vigorous stirring and the resulting white precipitate was collected and recrystallized from an ethanol-acetonitrile mixture to give 16.2 g of the tosylate, mp 157.5-158.5C.

Part C:
A mixture of 15.3 g (37.4 mmol) of ( ~ )-5-hydroxymethyl-3-(4-phenylphenyl)-2-oxazolidinone ~-toluenesulfonate, 0.2 g of 18-crown-6 and 2.7 g (41.1 mmol, 10% excess) of sodium azide in 60 mL of dry dimethylformamide (DMF) was heated at 70C (+5) for 5 hours and the mixture was poured into 300 mL of ice water to give a white precipitate. The precipitate was collected on a filter to give 10.4 g of the desired azide as a colorless solid, mp 163.6-164.5C.

Example 2 Preparation of (R )-5-Aminomethyl-3-(4-phenylphenyl)-2-oxazolidinone (I, Ar=C6H5, B=NH2) ( ~)-5-Azidomethyl-3-(4-phenylphenyl)-2-oxazolidinone (10.4 g) suspended in 200 mL of 95%
ethanol was hydrogenated in the presence of 0.7 g of platinum oxide under 40-50 psig (2.76x105-3.45x105 pascals) of hydrogen. The catalyst was removed by filtration through a bed of Celite~, the bed was washed with tetrahydrofuran (THF) and the combined ethanol filtrate and THF washings were concentrated under reduced pressure to give 9.2 g * trade mark ~, 1 . ,~ .
~,.

of the desired amine as a colorless solid, mp 140-141C.

ExamPle 3 Preparation of (~) -N- [3-(4-Phenylphenyl)-2-oxooxazolidin-S-ylmethyl]acetamide (I, Ar=C6H5, B=NHCOCH3 ) -To a solution containing 9.2 g of (~)-5-amino-methyl-3-(4-phenylphenyl)-2-oxazolidinone and 8 mL
of triethylamine in 200 mL of dry THF was added 3.5 mL of acetyl chloride dissolved in 10 mL of THF
dropwise at 0-10C. The mixture was concentrated under reduced pressure and the residue was triturated with water to give a solid which was recrystallized from ethanol to give 8.7 g of the pure amide as a colorless solid, mp 226-227OC.
Anal. Calcd for Cl8Hl8N23: C, 69.66; H, 5.85; N, 9 . 03.
Found: C, 69.44; H, 5.94; N, 9.03.
69.48 5.85 9.04.
ExamPle 4 Preparation of (~)-N- [ 3-(4-(4'-Acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=cH3coc6H4~ B=NHCOCH3) To 50 g of trifluoromethanesulfonic acid was added 7.5 mL of acetic anhydride dropwise at 0-50C
followed by 2.5 g of (e)-N-[3-(4-phenylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide. The mixture was stirred at room temperature for 3 hours and added dropwise to 500 mL of ice water with vigorous stirring. The resulting yellowish precipitate was collected and recrystallized from ethanol to give 2.6 g of the product as a faintly yellowish white solid, mp 261.5-262.5C.

~, Anal. Calcd for C20H20N24: C, 68.17; H, 5.72; N, 7.95.
Found: C, 67.87; H, 5.73; N, 7.92 67.93 5.79 7.84.
5By using the procedures described in Examples 1-4, the following compounds in Table I were prepared or can be prepared.
Table I

o X~N o Y B

Iso-Ex. X Y B mer m.p.(oC) H H N3 e 163.5-164.5 2 H H NH2 e 140-141 3 H H NHCOCH3 e 226-227 4 4'-CH3CO H NHCOCH3 e 261.5-262.5 4 ' - CH3CO H NHCO2CH3 e 6 4'-CH3CO H NHSO2CH2Cl e 7 4 ' -CH3CH2CO H NHCOCH3 e 253 8 4 ' -ClCH2CO H NHCOCH3 e 225 9 4 ' -HO2C (CHa) 2CO H NHCOCH3 e 240-241 4'-HO2CC(CH3) 2CH2CO H NHCOCH3 e 222 (dec) 11 a-C3H, H -NH2 e 12 n- C3H, H -NHCOCH3 e 13 a-C5Hll H ~NHCOCH3 e 14 C2Hs 3 ' -CH3 -N3 e C2Hs 3 ' -CH3 -NHCOCH3 e 16 H 3 ' -Cl -NHCOCH3 e 17 Cl 3 ' -CH3 -NHCOCH3 e 18 C2Hs 3 ' -F -NHCOCH3 e 19 CH3 3 ' -F -NHCOCH3 e . . ~

_ 36 l 337526 Example 20 Preparation of (e)-N-[3-(4-(4'-Iodophenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-IC6H4, B=NHCOCH3) (e)-N-[3-(4-Phenylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (20 g, 0.064 mole) in a mixture of trifluoracetic acid (170 mL) and acetic acid (570-mL) was stirred and heated a~ 60OC while adding dropwise a solution of iodine monochloride (139.2 g, 0.86 mole) in acetic acid (225 mL) during 6-7 hours. The mixture was stirred at 60OC
overnight, cooled to room temperature and filtered.
The resulting filter cake was washed with ether (to remove excess iodine) and dried to give the desired iodo compound as a tan solid (20.8 g, 74~) which was 94~ pure by HPLC. The filtrate was diluted with water and filtered to separate additional product 3.4 g. The main fraction was dissolved in dimethylformamide (200 mL) and filtered through a shallow beds of Darco~ and then Celite~. The filtrate was diluted with water (30 mL) and cooled to give pure product (9.1 g), mp 265-267OC.
Example 21 Preparation of ( e ) -N-[3-(4-(4'-Formylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-HCOC6H4, B=NHCOCH3) (e)-N-[3-(4-(4'-Iodophenyl)phenyl)-2-oxooxazo-lidin-5-ylmethyl]acetamide (4.41 g, 0.01 mole) was refluxed in dry tetrahydrofuran (500 mL) and flushed throughly with gaseous CO.
Tetrakis(triphenyl-phosphine)palladium(0) (2.35 g, _ 37 1 337526 0.002 mole) was added and the mixture stirred and heated at 50OC under slight positive pressure of CO
(balloon) while adding tributyltinhydride (2.94 g, 0.01 mole) in dry toluene (50 mL) during 6 hours.
Heating and stirring under gaseous CO pressure was continued overnight. The reaction mixture was cooled to room temperature, added to petroleum ether (600 mL) and filtered to separate the desired aldehyde (3.33 g, 97~). Recrystallization from acetonitrile gave pure aldehyde product as fibrous white needles, mp 210C.
The aldehyde can be readily converted to the corresponding carboxylic acid by oxidation with chromic acid in acetic acid.

ExamPle 22 Preparation of (e)-N-[3-(4-(4'-(1-Hydroxyiminoethyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3C(=NOH)C6H4, B=NHCOCH3) A mixture of 2.8 g of (e)-N-[3-(4-(4'-acetyl-phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]- -acetamide, 5.6 g of hydroxylamine hydrochloride and 11.2 mL of pyridine in 560 mL of absolute ethanol was heated under reflux for 3 hours and the mixture was allowed to cool to room temperature. The solid formed was collected and washed with ethanol to give 2.58 g of the desired crude oxime, mp 268-272OC. It can be further purified by recrystaa~ization from ethanol.

_ 38 Exam~le 23 Preparation of Sodium Salt of Succinate Hemiester of (Q)-N-[3-(4-(4~-(1-Hydroxyiminoethyl)phenyl)-phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3C(=NOCOCH2CH2CO2Na)C6H4, B=NHCOCH3) To a suspension of 1 g (2.72 mmol) of (e)-N-[3-(4-(4/-(l-hydroxyiminoethyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide in 30 mL of DMF
was added 135 mg (2.8 mmol) of NaH (50~ dispersion in mineral oil) and the mixture was heated slowly to 400C when it became clear momentarily, then a massive precipitate formed as it was heated to 500C
for 1 hour. The mixture was allowed to cool to 400C, and 0.272 g (2.72 mmol) of succinic anhydride dissolved in a-minimum volume of DMF was added.
The thick white precipitate became opaque and easier to stir. It was heated at 500C for 0.5 hours, cooled to room temperature, and the precipitate was filtered and washed successively with DMF, glyme and ether to give 1.05 g of the sodium salt as a colorless white solid, mp 297-3000 (dec).
Example 24 Preparation of (e)-N-[3-(4-(4'-(1-Carboxymethoxyliminoethyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3C(=NOCH2CO2H)C6H4, B=NHCOCH3) A mixture containing 1 g of (e)-N-[3-(4-(4'-acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 2 g of carboxymethoxylamine hydrochloride and 4 mL of pyridine in 180 mL of absolute ethanol was heated under reflux for 3 hours. The mixture was allowed to cool and white precipitate formed was collected and washed with ethanol to give 0.8 g of the desired product, mp 232OC (dec). The sodium salt of the acid can be prepared by treating with aqueous sodium hydroxide and removing the water.

- Example 25 Preparation of (~)-N- [3-(4-(4'-Acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide 4-Methylpiperazinylhydrazone (I, Ar=4'-CH3C (=NN (CH2CH2) 2NCH3) C6H4, B=NHCOCH3) (Q)-N-[3-(4-(4~-Acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (2.5 g, 0.0071 mole) and l-amino-4-methylpiperazine (2.04 g, 0.018 mole) were heated at reflux in dry dioxane (350 mL) with borontrifluoride etherate (0.30 mL) overnight.
The solvent was removed on a rotary evaporator and the product dried (80C/0.1 mm) to give the titled hydrazine (3.19 g, 100%), mp 200OC (dec).

ExamPle 26 Preparation of (~) -N- [3-(4-(4'-(1-(4-Methylpiperazinylamino)ethyl))phenyl)phenyl-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3CH (NHN (CH2CH2) 2NCH3) C6H4, B=NHCOCH3) (~) -N- [3-(4-(4'-Acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide 4-Methylpiperazinylhydrazone (3.57 g, 0.0079 mole) was heated in methanol (250 mL) at reflux and then cooled to room temperature. A solution of NaBH3CN
(0.5 g, 0.0079 mole) and ZnCl2 (0.5 g, 0.004 mole) in methanol (20 mL) was added and the mixture stirred at room temperature overnight followed by ~ 40 1 337526 reflux for 0.5 hour. The reaction mixture was added to saturated Na2CO3 (75 mL) and water (200 mL) and extracted with CH2Cl2/MeOH (9/1, 5 x 100 mL). The extract was dried (MgSO4) and the solvent removed on a rotary evaporator to give the product (2.91 g, 82~). The product was dissolved in 1 N
HCl (10 mL) and water (200 mL) and filtered to separate a solid (0.24g). The clear filtrate was divided into two equal parts. One part was made basic with sodium carbonate and extracted with CH2Cl2/CH3OH (9/1, 3 x 100 mL), dried and the solvent removed to give pure product (1.26 g), mp 120OC. The second portion was freeze dried to give the hydrochloride salt of the product (1.2 g), mp 168C (dec).

ExamPle 27 Preparation of (~)-N-[3-(4-(4'-(1-Hydroxyethyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4' -CH3CH(OH)C6H4, B=NHCOCH3) To a suspension of 0.39 g of (~)-N-[3-(4-(4'-Acetylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]-acetamide in 100 mL of 95~ ethanol was added 0.2 g of NaBH4. The mixture was slowly heated to its boiling point when the mixture became homogeneous.
Heating was continued for 15 minutes, diluted with 100 mL of water, brought it back to boiling, allowed to cool to room temperature and stripped to dryness. The resulting solid was triturated with water to give 0.36 g of white solid, mp 203.5-208.5OC. It was recrystallized once from ethanol to give 0.26 g of the desired alcohol as white solid, mp 207.5-212.5C.

t 337 526 _ 41 Anal. Calcd for C20H22N2O4: 354.1577 (M~) Observed m/e by HRMS: 354.1567.

By using the procedures described in Examples 20-27, the following compounds in Table II were prepared or can be prepared.

_ 42 l 337526 Table II

X~N O

' -Iso-Ex. X B mer m.p.(oC) 4'-I NHCOCH3 1 265-267 21 4'- HCO NHCOCH3 e 210 22 4'-CH3C (=NOH) NHCOCH3 e 268-272 23 4'- CH3C ( =NOCOCH2CH2CO2Na ) NHCOCH3 e 297-300 (dec) 24 4'-CH3C (=NOCH2CO2H) NHCOCH3 e 232 (dec) 4'-CH3C=NN (CH2CH2) 2NCH3) NHCOCH3 e 200 (dec) 26 4'-CH3CH (NHN (CH2CH2) 2NCH3) NHCOCH3 e 168 (dec) 27 4'-CH3CH (OH) NHCOCH3 e 207.5-212.5 28 4'-HOCH2 NHCOCH3 e 235 29 4'-CH3CH (OCOCH2CH2CO2H) NHCOCH3 e 156 4 ' -CH3CH (OCOCH2CH2CO2Na) NHCOCH3 e 31 4 ' -CH (=NOH) NHCOCH3 e 32 4'-CH (=NOCH2CO2H) NHCOCH3 e 33 4'- CH ( =NN ( CH2CH2 ) 2NCH3 ) . - NHCOCH3 e 34 4 ' -CH3CH2C (=NOH) NHCOCH3 e 4 ' -CH3CH2C (=NOCOCH2CH2CO2H) NHCOCH3 e 36 4'-CH3CH2CH(OH) NHCOCH3 e .- -' Exam~le 37 Preparation of (e)-N-[3-(4-(4'-Cyanophenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-NCC6H4, B=NHCOCH3) (l)-N-[3-(4-(4~-Iodophenyl)phenyl)-2-oxooxazo-lidin-5-ylmethyl]acetamide (20.10 g, 0.046 mole) and cuprous cyanide (16.0 g, 0.16 mole) in N-methylpyrrolidinone (270 mL) were stirred andheated at 125OC for 24 hours. The reaction mixture was cooled to room temperature, poured into ice water, and filtered to separate a brown solid. The solid was added to a column packed with silica (84 g) and eluted with CHC13/CH30H (9/1, 1000 mL) and methanol (750 mL). The combined eluents were evaported to dryness on a rotary evaporator to give the product (12.6 g, 81~) which was 96~ pure by HPLC. This material was recrystallized from chloroform to give the pure cyano compound, mp 208-2090C.
Anal calcd: C,68.05; H,5.11; N,12.53 Found: C,68.14; H,5.14; N,12.40 68.05 5.06 12.49 HRMS m/e calcd:335.1270, measured 335.1268 Example 38 Preparation of (~)-N-[3-(4-(4'-(5-Tetrazolyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-N4CC6H4, B=NHCOCH3 (~)-N-[3-(4-(4'-Cyanophenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (2.68 g, 0.0080 mole) was heated in dimethylformamide (25 mL) with trimethylsilyl azide (1.89 g, 0.016 mole) at 140C
for 5.5 hours. More azide (1.8 g, 0.016 mole) was ~ 44 1 337526 added and heating at 140OC was continued for a total of 45 hours. The reaction mixture was poured onto ice and centrifuged to separate a brown solid which was washed with water and dried ~2.71 g, 90~). The product was purified by chromatography on silica and eluted with CHCl3/CH30H (9/1) and then with methanol. The methanol fraction proved to be the pure product, mp 244OC (dec). The sodium salt of the product can be prepared by treating with aqueous sodium hydroxide and removing the water.

Example 39 Preparation of (e)-N-[3-(4- (4' - ( (N,N-Methylethylamino)methyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar-4'-CH3CH2N(CH3) CH2C6H4, B=NHCOCH3 (e) -N- [3-(4-(4'-Formylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide ~1.7 g, 0.005 mole) and ethylmethylamine (1.48 g, 0.025 mol) were heated at reflux in methanol (170 mL). The mixture was cooled to 25OC and a solution of sodium cyanoborohydride (0.315 g, 0.005 mole) in methanol (12.1 mL) was added and the mixture stirred at room temperature overnight. The reaction mixture was added to saturated sodium bicarbonate (25 mL) and water (100 mL) and extracted with CH2Cl2/MeOH (9/1, 3 x 100 mL). The extract was dried (MgSO4), filtered and the solvent removed on a rotary evaporator to give a white solid which was triturated with ether and dried to give the product (1.65 g, 86~). The product was dissolved in 1 N
HCl (10 mL) and water (150 mL) to give a clear solution. One half of this solution was made basic ~ 45 1 337526 with sodium carbonate and extracted with CH2Cl2/CH3OH (9/1, 3 x 100 mL). The extract was dried (MgSO4), filtered and the solvent removed to give pure amine (0.84 g), mp 162-164C. The residual acidic solution was freeze dried to give the hydrochloride salt of the amine (0.32 g), mp 145-147C (dec).
With primary amines, the reaction may stop at the imine stage when the reduction is carried out -:
-at room temperature. Refluxing the reaction mixture for 1-3 hour with a small excess of NaBH3CN or NaBH4 completes the reduc~ion.
Reductive alkylation of ketones frequently fails with NaBH3CN/ZnCl2 but the intermediate hydrazone can be prepared and reduced as described previously in Example 27.
By using the procedures described in Examples 37-39, the following compounds in Table III were prepared.

46 l 337526 Table III

X ~N~

Iso-Ex. X B mer m.p.(oC) 37 4'-NC NHCOCH3 e 208-209 38 4'-N4C NHCOCH3 e 244 (dec) 39 4'-CH3CH2N(CH3) CH2 NHCOCH3 e 162-164 4'-CH3NHCH2 NHCOCH3 e 197 (dec) 41 4~-( CH3 ) 2NCH2 - NHCOCH3 e 197 42 4'-CH3CH2NHCH2 NHCOCH3 e 180 43 4'-(CH3CH2)2NCH2 NHCOCH3 e 137 (dec) 44 4~-(B-Pr)2NcH2 NHCOCH3 e 128 4'-B- C4HgNHCH2 NHCOCH3 e 200 46 4'-(B- C4Hg ) 2NCH2 NHCOCH3 e 107 47 4'-(n-C5Hll)2NCH2 NHCOCH3 e 142 48 4 -B- C8Hl7N=CH NHCOCH3 ~ 210 49 4'-B- C~Hl7NHCH2 NHCOCH3 e 209 4'-(HOCH2CH2)2NCH2 NHCOCH3 e 123 51 4'-CH3N (cH2cH2) 2NNHCH2NHCOCH3 e 194 (dec) 52 4'-CH3COCH-NCH2-HCl NHCOCH3 e 100 53 4~- ~ CH2 NHCOCH3 e 54 4'-CH3OCH2CH2CH2NHCH2 NHCOCH3 e 55 4'-(CH3) 2NcH2cH2NHcH2 NHCOCH3 e 56 4'-CH3 ~ NCH2 NHCOCH3 e -_ 47 Example 57 Preparation of (e)-N-[3-(4-(4'-(3-N,N-dimethylaminopropionyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-(CH3)2NCH2CH2COC6H4, B=NHCOCH3) N,N,N',N!-Tetramethyldiaminomethane (0.29 g, 0.0028 mole) was added dropwise to trifluoroacetic acid (5 mL) cooled at -10C and stirred for 10 minutes. (e)-N-[3-(4-(4'-Acetylphenyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (1.0 g, 0.0028 mol) was added slowly as a solid at -10C. The cooling bath was removed and the mixture stirred while warming slowly to room temperature. The reaction temperature was then gradually raised to 60-65OC and heated at this temperature overnight.
The reaction mixture was added dropwise to saturated sodium carbonate (50 mL) cooled in an ice bath. The resulting mixture was filtered and the yellow solid washed with water and dried to give the product, 1.12 g, 97~, mp 192-194C.
A portion of the product (0.5 g) was dissolved in 1 N HCl (10 mL) and water (50 mL), filtered and the clear yellow solution freeze dried to give hydrochloride salt of the ketoamine (0.4 g), mp 150C gassing, 195C (dec).
When the Mannich resection was carried out using bis-(N-methylpiperidinyl)methane and propionyl derivative (I, Ar=4'-CH3CH2COC6H4-, B=NHCOCH3), an elimination product (I, Ar=4'-CH2=C(CH3)COC6H4-, B=NHCOCH3) was also obtained (Example 63).

~r .

~- - 48 1 337526 Example 58 Preparation of (~)-N- [3-(4-(4'-(3-N,N-Dimethylamino-l-hydroxypropyl)phenyl)phenyl)-2-5 oxooxazolidin-S-ylmethyl] acetamide (I, Ar=4'-(CH3)2NcH2cH2cH(oH)c6H4~ B=NHCOCH3) (~)-N- [3-(4-(4'-3-N,N-Dimethylamino-propionyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl] acetamide (3.14 g, 0.0077 mole) in acetic acid (35 mL) was stirred with NaBH3CN (1.93 g) at room temperature overnight. The solution was added dropwise to saturated sodium carbonate (400 mL) and the pH adjusted to 9-10. The mixture was extracted with CH2Cl2/CH30H, (9/1, 4 x 150 mL). The extract was dried and the solvent removed tO give the crude reduced amine (2.74 g, 87~). The compound was chromatographed on silica gel by eluting with CHCl3/CH30H (9/1) to give pure amine, mp 194C. A
20 portion of the amine was dissolved in dilute HCl and freeze dried to give the hydrochloride salt.
By using the prodcedures described in Examples 57 and 58, the following compounds in Table IV were prepared or can be prepared.

~ 49 l 337526 Table IV

X~N o - -Iso-Ex. X B mer m.p. (oc) 57 4 ' - (CH3) 2NCH2CH2CO NHCOCH3 e 192 -194 58 4 ' - (CH3) 2NCH2CH2CH (OH) NHCOCH3 e 194 59 4 ' -O (CH2CH2) 2NCH2CH2CH (OH) NHCOCH3 e 165 4 ' -CH3N (CH2CH2) 2NCH2CH2CO NHCOCH3 e 221 61 4 ' -CH3N (CH2CH2) 2NCH2CH2CH (OH) NHCOCH3 e 151 (dec) 62 4 ' -CH3N (CH2CH2) 2NCH2CH (CH3) CO NHCOCH3 e 105 63 4 ' -CH2=C (CH3) CO NHCOCH3 e 216 64 4 ' -CH3N (CH2CH2) 2NCH2CH (CH3) CH (OH) NHCOCH3 e 180 -Example 65 Preparation of (e)-N-[3-(4-(3'-Methylsulfenyl-phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=3'-CH3SOC6H4, B=NHCOCH3) To a mixture containing 23.4 g (0.1 mol) of ( e ) -N-(3-phenyl-2-oxooxazolidin-5-ylmethyl)acetamide and 29 g (0.13 mol) of silver trifluoracetate, 300 mL of acetonitrile and 200 mL
of chloroform was added 27 g of iodine in one portion and allowed to stir at room temperature overnight. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a brown solid which was triturated with distilled water, filtered and washed thoroughly with distilled water. The resulting solid was recrystallized from 200 mL of acetonitrile (activated charcoal used) to give 27.5 g (77%) of (e)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (XXIV) as a colorless crystalline solid, m.p. 194.5-195.5C.
A Grignard reagent was prepared from 25 g (0.123 mol) of _-bromothioanisole and 3.59 g (0.148 mol) of magnesium in 125 mL of tetrahydrofuran.
This solution was added to 56.8 mL (0.246 mol) of triisopropylborate in tetrahydrofuran at -70OC.
The borate ester was hydrolyzed with 10% sodium hydroxide solution, then acidified to give the boronic acid. Recrystallization from water gave 11.0 g of the boronic acid, mp 162-163C.
A mixture of 2.5 g (0.015 mol) of the above boronic acid in 40 mL of DMF, 4.2 mL of triethylamine, 3.6 g of (e)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 0.2 g of tri-2-tolylphosphine and 80 mg of palladium acetate was ~ 51 1 337526 subjected to four "Firestone" cycles. The homogeneous solution was held at 100C under nitrogen for 72 hours, cooled, and filtered. The DMF was removed at 70OC (0.5 mm Hg) and the residue dissolved in methylene chloride and washed with 10 ammonium hydroxide solution, dried over magnesium sulfate and solvent evaporated to give 2.31 g of crude material which was chromatographed on 70 g of silica gel with an eluent of methylene chloride-acetone to give 1.24 g of material consistent with product. Recrystallization from acetonitrile gave 0.8 g of pure (e)-N-[3-(4-(3'-methlthio-phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
A mixture of 0.51 g (0.0014 mol) of thesulfide in 155 mL of chloroform was held at reflux to dissolve the solid, then cooled to -30OC, and a solution of 0.30 g (0.0014 mol) of 82~ _-chloroperbenzoic acid in 15 mL of methylenechloride was added at -30OC, then allowed to warm to -20OC. After addition of 0.1 mL of dimethylsulfide, the mixture was warmed to 20OC and the solvent removed. The residue was dissolved in chloroform and washed with saturated sodium bicarbonate solution, dried over potassium carbonate and solvent evaporated. The residue was chromatographed on 25 g of silica gel with methylene chloride-acetone as~the eluent. The product was dissolved in water, fil~ered (0.2 micron membrane filter) and the water removed. The residue was recrystallized from isopropanol to give 180 mg of the sulfoxide, mp 162-167C. lH-NMR
(d6-DMSO) ~ 8.27 (m,lH), 7.93 (s,lH), 7.80 (m,3H), 7.67 (m,4H), 4.73 (m,lH), 4.20 (t,lH), 3.80 (t,lH), 3.45 (m,2H), 2.80 (s,3H), 1.83 (s,3H); IR (~3r):
3280, 1750; 1665, 1610, 1520, 1050 cm~l.

~, _ 52 l 337526 The sulfoxide can further oxidize to sulfone by reacting with excess MCPBA in chloroform under reflux for 3 hours.

Exam~le 66 Preparation of (Q)-N-[3_(4_(4'-N,N-Dimethylaminoethyloxyphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-(CH3)2NCH2CH20C6H4, B=NHCOCH3) A freshly prepared solution of 4-benzyloxphenyl magnesium bromide (from 21.05 g of 4-benzyloxybromobenzene and 2.2 g of magnesium metal) in tetrahydrofuran (80 mL) was added carefully to a stirred solution of freshly fused zinc chloride (17.14 g) in tetrahydrofuran maintained at 0-50C. The resulting mixture was stirred at room temperature for 30 minutes and then treated with (e)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-yl]methylacetamide (14.4 g), added in one lot, followed by the addition of bis(triphenylphosphine)nickel(II) chloride (4.0 g).
The mixture was stirred at room temperature for 90 minutes and then poured into an excess of ice and 1 N HCl and the solid that separated filtered off, washed with water, boiled with tetrahydrofuran and filtered. The solid was washed with a small quantity of tetrahydrofuran followed by hexanes and air-dried to yield 9.72 g of (~)-N-[3-(4-(4'-benzyloxyphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless solid, mp 235-2370C (dec). It was pure enough to be used in the next step. An analytical sample was prepared by recrystallizing a small quantity of the product from acetic acid, mp 243-2450C (dec).

~,.; ~ "

A suspension of the benzyloxy compound (6.74 g) in a solution of hydrogen bromide in acetic acid (72 mL; 30.32~) was stirred and heated under reflux for 10 to 15 minutes, cooled and filtered. The colorless solid was washed with ether and air-dried to yield (Q)-N-[3-(4-(4~-hydroxyphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (4.03 g), mp 280-281C (dec).
~Sodium hydride (0.5 g; 50~ oil dispersion) was added in small portions to a stirred solution of the phenolic compound (3.26 g) in warm dimethylformamide (75 mL) and, after the addition was complete, the mixture was stirred at room temperature for 15 minutes and then treated with a freshly prepared solution of 2-dimethylaminoethyl chloride (from 6.0 g of the hydrochloride and aq NaHCO3) in benzene (30 mL) added in one lot. The resulting mixture was stirred and heated at 90-100C overnight and then stripped of the solventsunder reduced pressure. The residue was triturated with water and filtered. The solid was dissolved in requisite volume of methylene chloride and the solution extracted twice with 1 N HCl (50 mL each time). The combined acid extracts were filtered to remove traces of undissolved material and the filtrate cooled and basified with conc. ammonium hydroxide. The mixture was extracted twice with methylene chloride and the combined methylene chloride extracts were washed with H2O, dried over MgSO4 and stripped of the solvent under reduced pressure to yield a solid which was recrystallized from isopropanol to furnish 1.4 g of (e) -N-[3-(4-(4'-N,N-Dimethylaminoethyloxyphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless solid, mp 202-204OC.

_ 54 Example 67 Preparation of (e)-N-[3-(4-4'-Methylthiophenyl)-phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3SC6H4-, B=NHCOCH3) A Grignard reagent was prepared from 12.2 g (0.06 mol) of ~-bromothioanisole and 1.7 g (0.07 mol) of magnesium in 70 mL of tetrahydrofuran.
0 This solution was added to 22.7 mL of triisopropylborate in tetrahydrofuran at -70OC.
The borate ester was hydrolyzed with 150 mL of 1 N
sodium hydroxide solution and most of the tetrahydrofuran from the mixture was removed under reduced pressure. Acidification of the basic solution with 10~ hydrochloric acid gave 9.28 g of the crude boronic acid. Recrystallization from water gave 3.8 g of pure ~-methlmercaptophenyl-boronic acid as a colorless, crystalline solid, m.p. 211.5-212C.
A mixture of 2.52 g (0.015 mol) of the above boronic acid in 40 mL of DMF, 4.2 mL of triethylamine, 3.6 g of (e)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 0.2 g of tri-2-tolylphosphine and 80 mg of palladium acetate under nitrogen atmosphere was heated at 100C for i2 hrs., cooled, and diluted with 40 mL of ether. The solid precipitate formed was filtered, washed successively with ether, water, sodium bicarbonate and water to give a crude product. The crude product was recrystallized once from ethanol to give 1.3 g of pure (~)-N-[3-(4-(4'-methylthiophenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, m.p. 244.5-246.5OC. HRMS:
Calcd. 356.1195; Measured, 356.1168.

."

-~ 55 1 337526 Example 68 Preparation of (e)-N-[3-(4-(4'-Methylsulfenylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3SOC6H4-, B=NHCOCH3) A mixture of 0.6 g (1.68 mmol) of the sulfide of Example 67 in 250 mL of chloroform was heated to dissolve the solid, then cooled to -30OC, and 0.36 (1.68 mmol) of 82~ _-chloroperbenzoic acid was added at -30OC, then allowed to slowly warm to -10. Trace of insoluble material was removed by filtration and the filtrate was diluted with ether to precipitate 0.59 g of the sulfoxide, m.p. 217-219C. The product was shown to be at least 99~
pure by hplc. An nmr (CDCl3) showed absence of any sulfone resonance. HRMS: Calcd. 372.1144;
Measured, 372.1156.
.
Example 69 Preparation of (e)-N-[3-(4-(4'-Methylsulfonylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4,-CH3SO2C6Hq-, B=NHCOCH3) A mixture of 0.4 g (1.1 mmol) of the sulfide of Example 67 and 0.53 g (2.45 mmol) of 82~ _-chloroperbenzoic acid in 200 mL of chloroform was heated under reflux for 2.5 h. The mixture was cooled and diluted with ether to precipitate the desired sulfone, 0.4 g, m.p. 259-260.5OC dec. The product was shown to be homogeneous by hplc. HRMS:
Calcd. 338.1089; Measured, 338.1126.
By using the procedures described in Examples 65-69, the following compounds in Table V were prepared or can be prepared.

. . ~

- 56 l 337526 Table V

o N O

Iso-Ex. X Y B mer m.p.(oC) 3 ' -CH3SO H NHCOCH3 e 162-167 66 4 ' - (CH3) 2NcH2cH2o H NHCOCH3 e 202-204 67 4 ' -CH3S H NHCOCH3 e 244.5-246.5 68 4 ' -CH3SO H ~rICOCH3 e 217-21g 69 4 ~ -CH3S02 H NHCOCH3 e 259-260.5 (dec) 3 ' -CH3CH2 H NHCOCH3 e 121-122 71 2 ' -CH3 H NHCOCH3 e 181-183 72 3 ' -HCO H NHCOCH3 e 146-147 73 3 ' -NH2 H NHCOCH3 e 220-221 74 3 ' - (CH3) 2N H NHCOCH3 e 163-163.5 4 ' -CH30 H NHCOCH3 e 239-241 (dec) 76 4' - (CH3)2N(CH2)3O H NHCOCH3 e 191-193 77 4 ' -C6H5CH2OCOCH2O H NHCOCH3 e 186-187 78 4 ~ -HO2OcH2O H NHCOCH3 e 228-230 (dec) 79 4 ' -F H NHCOCH3 e 229-230 (dec) 4 ' -Cl H NHCOCH3 e 249-250 (dec) 81 4 ' - CH3 5 ' - CH3 NHCOCH3 e 168 - 169 82 3 ' - CH3 5 ' - CH3 NHCOCH3 e 106 - 107 83 4 ' -F 5 ' -F NrICOCH3 e 201.5-203 84 3 ' -F 5 ' -F NHCOCH3 ~ 204-204.5 _ 57 ExamPle 85 Preparation of (~)-N-[3-(4-(4-Pyridyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-NCsH4, B=NHCOCH3 To a stirred solution of 75 g (0.386 mol) of 4-brol..o~ridine hydrochloride in 400 mL of ether and 200 mL of water (2 layer system) was added 40 g of sodium carbonate (0.38 mol) in several portions.
The water was separated, the ether layer was washed once with brine, dried (MgSO4) and most of the solvent was removed under reduced pressure. As soon as the vacuum started to improve indicating that most of the ether was removed, 200 mL of fresh anhydrous ether was added and the solvent was again removed. This process was repeated once more to m; n;m;ze any moisture present. To the residue still cont~;n;ng small amount of ether was added 750 mL of ether immediately. The solution was cooled to -780C, and 185 mL (0.462 mol, 20~ excess) of 2.5 N B-butyllithium (in hexane) was added at such a rate that the temperature of the reaction mixture remained below -65OC (~20 min). When the temperature returned to below -70O, 92.2 g (0.463 mol) of trimethyltin chloride dissolved in 200 mL of ether was added at below -65OC. When the addition was complete, it was stirred at -75OC for 0.5 hour, and then the cooling bath was~removed to allow the temperature of the reaction to slowly rise. When the temperature of the reaction reached -20OC, 10 mL
of methanol followed by 200 mL of water were added and the mixture was allowed to cone to room temperature. The ether layer was washed once with brine, dried (MgSO4) and the solvent was evaporated under reduced pressure to give 114 g of a light tan .

, ~,;~ .

~ 58 1 337526 liquid. The pure product was isolated by distillation through a 30 cm Vigreux column, bp 40-42OC (0.1 mm), [bp 32-34OC (0.07 mm)]. a-Butyltrimethyltin, a by-product, distills at below room temperature at this pressure and separates well by distillation through the 30 cm Vigreux column.
A mixture containing 74.5 g (0.207 mol of (Q)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 60 g (0.248 mol) of 4-pyridyltrimethyltin, 23 g (0.033 mol) of freshly prepared bis(triphenylphosphine)palladium(II) chloride and 71 mL of triethylamine in 1300 mL of dry dimethformamide (DMF) was heated at 50-60OC
until all of the iodophenyloxazolidinone is used up (24-28 hours) as monitored by HPLC. The insoluble catalyst was removed by filtration through a bed of Celite~ and the volatile material and all of the solvent (DMF) from the filtrate was removed under reduced pressure (~40OC). The resulting oil was taken up in 500 mL of chloroform and diluted with 1.5 L of ether to give a tan precipitate. The precipitate was filtered and dried under a stream of nitrogen, digested with 1 L of 1 N HCl, filtered to remove insoluble material and neutralized to pH of 8 using conc. ammonium hydroxide at 10-20C. The off-white precipitate was collected on a filter, dissolved in 400 mL of hot 95~ ethanol, treated with charcoal, and diluted with 700 mL of water. The solution was concentrated under reduced pressure to remove most of the ethanol to give an off-white precipitate. The precipitate was collected on a filter and washed with a small amount of ice water and dried to give 26 g (40.3~ theory) of the product, mp 188-190C. Several other runs conducted under the same conditions gave products in 40-45 yields. The material can be further purified by recrystallization from absolute ethanol, or repeating the work-up procedure to give analytically pure sample of (e)-N-[3-(4-(4-pyridyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless white solid, mp 191-192C.
Anal. Calcd for C1,H17N3O3: C, 65.58; H, 5.50; N, 13.50 Found: C, 65.33; H, 5.67; N, 13.37 65.35 5.53 13.38 --Following a procedure similar to the one described in Example 65, amine oxide derivatives of the pyridyl compounds were prepared by treating with excess MCPBA.
~-N-[3-(4-Tri-g-butylstannylphenyl)-2-oxooxazolidin-5-yl-methyl]acetamide was prepared as follows.
To a mixture of 7.0 mL of hexabutylditin, 3.60 g of (Q)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]-acetamide and 25 mL of DMF under nitrogen, which had been subjected to several Firestone cycles to remove oxygen, was added 0.16 g of (PhCN)2PdCl2 with stirring and the mixture was stirred at 70OC overnight. The mixture was poured into 500 mL of water and extracted with ethyl acetate, which was dried (MgSO4), filtered through a Celite~ pad to remove both Pd and the MgSO4, and evaporated in vacuo. The mixture was chromatographed on silica with chloroform to give the pure (~)-N-[3-(4-tri-g-butylstannylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide free from tributyltin iodide by-product as a cont~m;n~nt.
Isolated was 3.21 g.
By using the procedures described in Example 85, the following compounds in Table VI were prepared or can be prepared.

Table Vl ~ N~

Iso-10 Ex. Ar B mer m.p. (-C) 4 ~-NCsH4 NHCOCH3 L 191-192 86 2 '-NC5H4 NHOOCH3 L 170-173 87 2 ~ -oNCsH4 NHCOCH3 L 110 (dec) 88 3 ' -NCsH4 NHCOCH3 L 183-185 89 3~oNc5H4 NHCOCH3 L 220 (dec) 9 0 4 ~ -oNC4H4 NHOOCH3 L
91 4 ' -ClC6H4 NHCOCX3 L 249-250 92 Q NHCOCH3 L 221-222 (dec) '~
93 ~ NHCOCH3 L 196 (Ak~) CH, 94 ~ NHCOCH3 L
CsH~ - .

Ck N~ NHCOCH3 dQ

CH, CH,~

1 337~26 Table VI
(Continued) Is~
E~c . Ar E~ mer m. p . ~ C ) ~j C~
97 N~ L
C H, 98 C~l, NHSa~H3 10 ~

59 9 N~ COC3H7 L
C~H~o 100 ~ N~S02C2H5 L
C~2 H

101 t ~ N~CH3 L

1' 0, 102 N~ N3 NC
103 ~ NH2 Q

30 104 C4H9sc>2N~ NH~3 L

Table VI
(Continued) EX. Ar B m~rm.p. (C) 105 Q~35 ~} N~3 L

106 c~3s~O-- ~3 L

107 C3H7NH~} N~XH3 L

108 ~ ~COa~3 L

lo9 ~ ~3 L

llo ~ 3 111 < 3 t~3 N

112 ~ ~_ ~3 L
N

_ 63 1 337526 Exam~le 113 Preparation of (Q)-N-[3-(4-(2',5'-Dihydroxyphenyl)-phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I,Ar=2',5'-(HO)2C6H4, B=NHCOCH3) (e)-N-[3-(4-Nitrophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide was prepared according to the procedures previously described in U.S. Patent 4,705,799. The nitro compound was reduced to the corresponding amino derivative by catalytic hydrogenation in 95~ ethanol in the presence of platinum oxide under 40 psig of hydrogen pressure.
To a mixture containing 1 g (4 mmol) of ( e ) -N-[3-(4-aminophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 1 mL of 28~ HCl and 4 g of ice was added a solution of 0.28 g of sodium nitrite in 1 mL of water dropwise at 0-5OC. After the addition was complete, the mixture was tested with starch/iodide paper to insure the reaction was complete. The mixture after being made neutral (pH
6-7) by cautious addition of sodium carbonate dropwise to a solution of 0.65 g (50~ excess) of benzoquinone dissolved in a m; n; m~lm amount (-15 mL) of 95~ ethanol with vigorous stirring at 10-15C.
The mixture was allowed to come to room temperature, stirred for 1 hour and diluted with 200 mL of water. The desired benzoquinone attached phenyloxazolidinone was obtained as a brick colored solid, 0.95 g, mp 218-219.5C. It was recrystallized once from acetonitrile to give 0.4 g of the pure quinone derivative as a golden orange solid, mp 235-236OC.
To the orange solid (1.6 g, 4.7 mmol) suspended in 45 mL of 95~ ethanol was added 0.5 g of sodium borohydride. A slight exotherm was noted and the mixture became homogeneous in 10 minutes.

~ .

_ 64 Water (50 mL) was added and the mixture was warmed to 500C. After allowing to cool, most of the ethanol was removed under reduced pressure and the resulting aqueous solution was made acidic (pH 1) with 6 M HCl to precipitate the product. The product was obtained as a light grayish purple solid, 1.03 g, mp 227-228.50C.

Example 114 Preparation of (~) -N- [3-(4-(4'-Ethylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=4'-CH3CH2C6H4, B=NHCOCH3) To 4'-ethylbiphenylcarboxylic acid (20 mmol) dissolved in 50 mL dry DMF was added 25 mmol of triethylamine and the mixture was cooled in an ice bath, added 38.5 mmol of methyl chloroformate dropwise at 0-50, and then stirred at room temperature for 15 minutes. The mixture was cooled to OoC again, and a cold solution of 38.5 mmol of sodium azide dissolved in a minimum amount of water (c8mL) was added as rapidly as possible (in one portion if possible) at ~50C. The reaction mixture was stirred at Ooc for 1 hour and poured into 500 mL of ice-water. The resulting precipitate was filtered while still cold (~10 min), washed with cQld water and dried under a stream of nitrogen to give the crude 4'-ethylbiphenylcarbonyl azide. The azide was used in place of 4'-ethylbiphenylisocyanate for the subsequent reactions according to the procedures exactly paralleling those described previously for Examples 1 through 3 to give the desired product as a colorless solid, mp 223-2240C.

, _ 65 l 337526 By using the procedures described in Examples 113 and 114, the following compounds in Table VII
were prepared or can be prepared.

--, .

~able VII
o Ar ~ N O
S ~

Iso-EX. Ar B mer m.p.(-c) 113 2~,5'-diOffc6~3 N~cocH3 L 227-228.5 114 4'-C2HsC6H4 3 L 223-224 115 4~-(c~3)2Nc6H4 NHCOC~3 116 4~-(cH3)2N(o)c6H4 N~C~L~3 125-127 117 4~-(9-fluorinon-2-yl) N~KocH3 L 237.5-238.5118 4~-(9-fluorinol-2-yl) ~COCH3 L 214-221 119 3'-02NC6H4 ~COCH3 L 140-141 20 120 ~ ~ NHOOCH3 dL

121 ~ C~CH3 d~

~ ' 122 ~ ~ NHDOCH3 CH) ' !

Table VII (continued) Iso--Ex. Ar B merm.p. (C) N~
~N

10 124 r~ NHCOCH3 Q
N~=~

12 5~N ~ NHCOCH3 Q
S~

2 0 12 6 rN NHCOCH3 Q
N~

25127 ,rN NHCOCH3 Q
N ~_ 128 ~N NHCOCH3 Q

N=~

35129 N~ NHCOCH3 e 209-211 ~N=r . ~ .

68 1 33~526 Example 130 Preparation of (e)-N- [3- [4-(5-Isoxazolyl)phenyl] -2-oxooxazolidin-5-ylmethyl]acetamide (I, Ar=5-5 isoxazolyl, B=NHCOCH3) A mixture of (~)-N- [3-(4-acetylphenyl)-2-oxooxazolidin-5-ylmethyl] acetamide (500 mg, 1.8 mmol) in 2 mL of dimethoxyformamide was heated at 110OC~overnight (16 hours). Excess dimethoxyformamide was removed in vacuo and the residue was purified by flash column chromatography to give 328 mg (55~) of (~)-N-[3-(4-(3-dimethylamino-2-ethenylketo)phenyl)-2-oxooxazolidin-5-ylmethyl] acetamide as a white solid. mp 191-192C; lH-NMR (CDC13) ~: 7.95 (d,J=7Hz,2H), 7.83 (d,J=13Hz,lH), 7.58 (d,J=7Hz,2H), 6.50 (m,lH), 5.75 (d,J=13Hz,lH), 4.83 (bs,lH), 4.12 (t,lH), 3.83 (dd,lH), 3.67 (m,2H), 3.17 (bs,3H), 3.00 (bs,3H), 2.05 (s,3H); MS: m/e 331.1537 (M~), calcd. for Cl,H2lN3O4: 331.1530.
A solution of the above compound (325 mg, 0.98 mmol) in methanol (3 mL) was treated with hydroxylamine-o-sulfonic acid (125 mg, 1.08 mmol) at room temperature for 45 minutes. It was poured into saturated sodium bicarbonate solution. The resulting solid was collected and washed with water to give, after drying, 167 mg (57~) of the product as a white solid. mp 175-178C (dec); lH-NMR (d6-DMCO) ~: 8.63 (bs,lH), 8.28 (bs,lH), 7.92 (d,J=7Hz,2H), 7.72 (d,J=7Hz,2H), 7.00 (bs,lH), 4.77 (bs,lH), 4.20 (t,lH), 3.82 (t,lH), 3.43 (m,2H), 1.87 (s,3H); MS: m/e 301.1081 (M~), calcd. for C1sHlsN3O4: 301.1061.

~ 69 l 337526 Example 131 Preparation of (e)-[3-(4-(2-Methyl-4-thiazolyl)phenyl)-2-oxooxazolidin-5-ylmethyl]azide (I, Ar=2-methyl-4-thiazolyl, B=N3) A solution of (~)-5-azidomethyl-N-[3-(4-actyl-phenyl-2-oxooxazolidin] (2.47 g, 9.5 mmol) in chloroform (30 mL) was treated with bromine (0.53 mL, 10.45 mmol) at room temperature for 15 minutes.
The solvent was removed and the residue was taken up with 10% methanol/methylene chloride. The resulting solid was filtered off and the solvent of the filtrate was removed to afford the crude product which was purified by flash column chromatography to yield 2.15 g (68%) of the bromoacetyl compound.
H-NMR (CDCl3) ~: 8.00 (d,J=7Hz,2H), 7.67(d,J=7Hz,2H), 4.83 (m,lH), 4.40 (s,2H), 4.15 (t,lH), 3.93 (dd,lH), 3.70 (2dd,2H).
A mixture of the above bromoacetyl compound (200 mg, 0.59 mmol) and thioacetamide (55 mg, 0.7 mmol) in toluene (3 mL) was refluxed for six hours.
The solvent was removed, the residue was diluted with 10% methanol/methylene chloride, washed with saturated brine and dried (Na2SO4). The crude product was purified by flash column chromatography to give 140 mg (76%) of the title compound, ~H-NMR
(d6-acetone) ~: 8.00 (d,J=7Hz,2H), 7.70 (d,J=7Hz,2H), 7.67 (s,lH), 5.00 (m,lH), 4.30 (t,lH), 4.00 (dd,lH), 3.83 (m,2H), 2.73 (s,3H).
The title compound was converted into its acet-amide compound (I, Ar=2-methyl-4-thiazolyl, B=NHCOCH3) by the procedure described in U.S. Patent 4,705,799.
By using the procedures described in Examples 130 and 131, the following compounds in Table VIII
were prepared or can be prepared.

-, ' 1 33752~
Table VIII

Ar ~

Iso-Ex. Ar B mer m.~.(C) 130 S-isoxazolyl NHCOCH3 ~ 175-178 131 2-methyl-4-thiazolyl N3 e NMR

132 2-methyl-r-thiazolyl NHCOCH3 e 179-180 133 lH-pyrazol NHCOCH3 e 235-136 (dec) 134 2-amino-4-thiazolyl NHCOCH3 e 171-174 (dec) 135 2-amino-4-pyrimidinyl NHCOCH3 e 258 (dec) 136 5-oxazolyl NHCOCH3 e 200 (dec) Dosaqe Form The antibacterial agents of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can ben administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration with standard pharmaceutical practice.

B

The dosage administered will, of course, vary depending upon known factors such as the pharmaco-dynamic characteristics of the particular agent, S and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment;
frequency of treatment; and the effect desired.
Usually, a daily dosage of active ingredient can be about~5 to 20 milligrams per kilogram of body weight. Ordinarily, when the more potent compounds of this invention are used, 5 to 15, and preferably 5 to 7.5 milligrams per kilogram per day, given in r divided doses 2 to 4 times a day or in sustained release form, is effective to obtain desired results. These drugs may also be administered parenterally.
Projected therapeutic levels in hllm~nq should - be attained by the oral administration of 5-20 mg/kg of body weight given in divided doses two to four times daily. The dosages may be increased in severe or life-threatening infections.
Dosage forms (compositions) suitable for internal administration contain from about 1.0 milligram to about 600 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5-95~ by weight based on the total weight of the composition.
The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

.~ '' i_ _ 72 Gelation capsules contain the acitve ingredient and powdered carriers, such as lactose, sucrose, manitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffer substances.
Antiooxidants such as sodium bisulfate, sodium sulfite, or ascorbic acid either alone or combined are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl-or propyl-paraben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remin~ton's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.

~ .

73 l 337526 Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows:
Capsules A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 75 milligrams of powdered active ingredient, 150 milligrams of lactose, 24 milligrams of talc, and 6 milligrams of magnesium stearate.

Soft Gela~in Capsules A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 75 milligrams of the active ingredient. The capsules are washed and dried.
Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit is 75 milligrams of active ingredient, 0.2 milligrans of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 250 milligrams for microcrystalline cellulose, 11 milligrams of cornstarch and 98.8 milligrams of lactose.
Appropriate coatings may be applied to increase palatability or delay absorption.

Iniectables A parenteral composition suitable for administration by injection is prepared by stirring 1.5~ by weight of active ingredient in 10~ by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

74 l 337526 SusPensions An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 75 milligrams of finely-divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.
Utility Test results indicate that the compounds of this invention are biologically active against gram positive bacteria including multiple antibiotic resistant strains of staphylococci and streptococci. These compounds are potentially useful for the treatment of both human and animal bacterial infections including diseases of the respiratory, gastrointestinal, genito-urinary systems; blood; interstitial fluids; and soft tissues.
As shown in Table IX, compounds of Formula (I) exert an in vitro antibacterial effect. A standard microdilution method (National Committee for Clinical Standards. Tentative standard M7-T.
Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA, 1982) with Mueller-Hinton broth is used to determine the 24-hour minimal inhibitory concentrations (MIC's) fortest strains of StaPhylococcus aureus and Escherichia coli.
The in vivo potency of these compounds is exemplified by the data summarized in Table X.
Determinations of in vivo efficacy are performed by inoculating mice intraperitoneally with cultures of ~ ,, 1 ~ -` 7S l 337526 the infecting organism diluted to produce 100~
mortality in control ~n;mAls within twenty-four hours. The culture of S. aureus used to infect the animals was diluted to the required bacterial density using 5~ aqueous hog gastric mucin. The compounds are dissolved or suspended in 0.25 aqueous Methocel~ (Methocel~: Hydroxypropyl Methylcullulose, E15 Premium, Dow Chemical Company) for oral adminstration of sterile distilled water containing 5~ dimethylsulfoxide (Fisher Scientific Company, Fairlawn, NJ) for subcutaneous administration. The mice are dosed at one hour and at four hours post-infection. Mortality is recorded daily until test determination seven days post infection. The number of survivors in each treatment group on the seventh day after infection is used in the calculation of the EDso~ the dose of compound that protects 50~ of the mice (Litchfield, J.T. and Wildoxon. A simulated method for evaluating dose-effect experiments. J. Pharmacol EXP. Ther., 98:99-113, 1949).

~able IX

In Yitro 8roth Microdilution ~mal Inhibitory Conoe ntrations (MIC' 6 ) s .

ExampleM~JLJ~Im Inhibitory Concentration No. (~g/mL) Staphylococcus aureus Escherichia coli 3 0.5 >128 4 0.5 >128 7 2 >128 8 <0.13 >128 9 <0.13 >128 0.5 >128 8 >128 21 <0.13 >128 22 0.25 >128 23 1 >128 24 8 >128 2 >128 26 1 >128 27 0.5 >128 2~ 28 <0.13 >128 29 4 >128 . 4 >128 37 0.25 >128 38 64 >128 43 4 >128 44 4 >128 ~ 45 0.5 >128 46 4 ~128 47 0.5 >128 77 l 337526 Table IX
(Continued) ExampleMinim~m Inhibitory Concentration No. S~9/~L) S
Staphylococcus aureus Escherichia coli 48 <0.13 >128 49 1 >128 0.5 >128 57 l >128 58 1 >128 59 2 >128 1 >128 61 2 >128 62 2 >128 63 0.25 >128 64 4 >128 2 >128 66 0.5 >128 67 0.25 >128 68 0.25 >128 69 0.25 >128 2 >128 71 2 >128 73 0.5 >128 74 8 >128 <0.13 >128 <0.13 >128 86 2 >128 87 32 >128 88 <0.13 >128 89 2 >128 92 2 >128 113 16 >128 ~ 78 1 337526 Table IX
(Continued) ExampleMinimlm Inhibitory Concentration No. (~g/mL) Staphylocoocus aureus Escherichia coli 114 0.5 >128 115 16 ?128 116 16 >128 117 4 >128 118 4 >128 119 <0.13 >128 130 1 >128 132 4 >128 133 4 >128 134 8 >128 135 4 >128 136 1 >128 3~

Table X

In Vivo Activity of C~roun~ Against staphylococcus Aureus in an Acute Lethal Mbuse Mbdel Example No. EDso-(mg/kg) Oral Sukcutaneous Administration P~inistration 3 2.9 2 4 22 39.7 7 NT >90 8 >90 >90 9 >90 16.8 1~
>90 >90 21 44.7 >90 22 >90 >90 23 17.3 24.3 24 >90 >90 13.9 5.8 27 6.6 7.6 28 52.6 30 29 16.1 9.8 16.1 9.8 37 <1.2 0.6 38 ~ >90 43 6.4 3.7 44 8.6 3.7 NT 13.9 Table X
(Continued) Example No. EDso (mg/kg) Oral Subcutaneous AdministrationA~ministration 49 65.2 >90 NT 6.5 58 13.8 2 59 7 2.7 61 47.4 2.7 62 51.9 10 63 >90 >90 NT 4.3 67 4.5 30 68 2.2 0.7 69 4 1.2 71 51.9 >90 73 11.8 5 74 NT 17.1 NT
1.3 0.5 ~6 ~T 15.5 87 16.1 9.8 88 1.6 O.s 89 2 <3.3 113 >90 68.3 3~

1 33752~

Table X
(Continued) Example No. EDso (mg/kg) Oral Sukcutaneous Ad~inistrationAdministration 114 8.1 >100 116 NT 6.4 119 6.2 5 134 S6.5 ~7 136 14.8 51.9 .

~ = Not Tested

Claims (41)

1. An aryl benzene oxazolidinone of the formula (I) wherein, for the ?, and mixtures of the d and ?
stereoisomers of the compound Ar is an aromatic group selected from the group consisting of , , a diazinyl group optionally substituted with X and Y, a triazinyl group optionally substituted with X
and Y, , , and ;

Z is O, S, or NR5;
W is CH or N, or also can be S or O when Z is NR5;
X independently is H, -NO2, -S(O)nR1, tetrazoyl, -S(O)2-N=S(O)pR2R3. -SH, , -COR23, -CONR5R6, , , , R6R5N-(CH2);, -CN, -OR5, halogen, -NR5R6, , , -CR23(OR16)OR17, of 1 to 8 carbons optionally substituted with one or more halogen atoms, OH, =O other than at alpha position, S(O)nR24, or NR5R6, alkenyl of 2-5 carbons or cycloalkyl of 3-8 carbons;
R1 is C1-C4 alkyl, optionally substituted with one or more halogen atoms, OH, CN, NR5R6 or CO2R8;

C2-C4 alkenyl; -NR9R10; -N3; ; ;
-NG2; NR9G-NGM+;
R2 and R3 are independently C1-C2 alkyl or, taken together are -(CH2)q-;
R4 is alkyl of 1-4 carbons, optionally substitu-ted with one or more halogens;
R5 and R6 are independently H, alkyl of 1-8 carbons, cycloalkyl of 3-8 carbons -(CH2)tOR8, -(CH2)tNR11R11a, or -O(CH2)tNR11R11a; or taken together are -(CH2)2O (CH2)2-, -(CH2)tCH(COR4)-, or ;
R7 is -NR5R6, -OR5 or R8 is H or alkyl of 1-4 carbons;
R9 is H, C1-C4 alkyl or C3-C8 cycloalkyl;
R10 is H, C1-C4 alkyl, C2-C4 alkenyl, C3-C4 cycloalkyl, -OR8 or -NR11R11A;
R11 and R11A are independently H or C1-C4 alkyl, or taken together, are -(CH2) r-;
G is C1, Br or I;
Y independently is H, F, Cl, Br, OR8, alkyl of 1-3 carbons, or NO2;
X and Y taken together (a) when Ar is or to form a fused six-membered carbocyclic ring, or (b) when Ar is to form M is a physiologically acceptable cation;
n is 0, 1 or 2;
p is 0 or 1;
q is 3, 4 or 5;
r is 4 or 5;
t is 1, 2 or 3;

, , B is -NH2, or N3;
R12 is H, C1-C10 alkyl or C3-C8 cycloalkyl;
R13 is H; C1-C4 alkyl optionally substituted with one or more halogen atoms; C2-C4 alkenyl;
C3-C4 cycloalkyl; phenyl; -CH2OR15;
-CH (OR16)OR17;

-CH2S(O)vR14; ; -OR18; - SR14;
-CH2N3;
the aminoalkyl groups derived from .alpha.-amino acids such as glycine, L-alanine, L-cysteine, L-proline, and D-alanine; -NR19R20; or -C(NH2)R21R22;
R14 is C1-C4 alkyl, optionally substituted with one or more halogen atoms;
R15 is H or C1-C4 alkyl, optionally substituted with one or more halogen atoms;
R16 and R17 are independently C1-C4 alkyl or, taken together, are -(CH2) m-;
R18 is C1-C4 alkyl or C7-C11 aralkyl;
R19 and R20 are independently H or C1-C2 alkyl;
R21 and R22 are independently H, C1-C4 alkyl, C3-C6 cycloalkyl, phenyl or, taken together, are -(CH2)s- ;
u is 1 or 2;
v is 0, 1 or 2;
m is 2 or 3;
s is 2, 3, 4 or 5;
R23 is H, alkyl of 1-8 carbons optionally substituted with one or more halogens, cycloalkyl of 3-8 carbons, alkyl of 1-4 carbons substituted with one or more of -S(O)nR24, -OR8, , or -NR5R6; or alkenyl of 2-5 carbons optionally substituted with CHO or CO2R8;
R24 is alkyl of 1-4 carbons or cycloalkyl of 3-8 carbons; and R25 is R6 or NR5R6;

or a pharmaceutically suitable salt thereof;

provided that:

1) when B is NH2, then Ar is not phenyl option-ally substituted with halogen or CF3.
2. An oxazolidinone of Claim 1 wherein B

is -NHCR13 where R13 is H, CH3, -OR18, CH2C1, CH2OH, or CH2OCH3.
3. An oxazolidinone of Claim 2 wherein B is O
-NHOCH3.
4. An oxazolidinone of Claim 1 wherein Ar is , , or
5. An oxazolidinone of Claim 4 wherein Y is H.
6. An oxazolidinone of Claim 5 wherein X is H, alkyl of 1-5 carbon atoms,-S(O)nCH3 where n is 0, 1 or 2, - OCH3, - OR5, - CH2NR5R6, R6R5N (CH2)2 O
CH(OH)-, or -CN.
7. An oxazolidinone of Claim 3 wherein Ar is , , or
8. An oxazolidinone of Claim 7 wherein Y is H.
9. An oxazolidinone of Claim 8 wherein X is H, alkyl of 1-5 carbon atoms, -S(O)nCH3 where n is 0 1 or 2, - OR5, - CH2NR5R6, R6R5N (CH2)2 CH(OH)-, or -CN.
10. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-phenylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
11. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-acetylphenyl)phenyl)-2-oxooazolidin-5-ylmethyl]acetamide.
12. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-methylsulfinylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
13. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-methylsulfonylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
14. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-cyanophenyl)phenyl-2-oxooxazolidin-5-ylmethyl]acetamide.
15. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-diethylaminomethylphenyl)-phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
16. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-di-?-propylaminomethylphenyl)-phenyl)-2-oxooxazolidin-5-ylmethvl]acetamide.
17. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-(3-N,N-dimethylamino-1-hydroxypropyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
18. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(4'-(1-hydroxy-3-(4-morpholinyl)-propyl)phenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide.
19. The oxazolidinone of Claim 7 which is (?) -N-[3-(4-(4'-pyridylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, hydrochloride.
20. The oxazolidinone of Claim 7 which is (?)-N-[3-(4-(3'-pyridylphenyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, hydrochloride.
21. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 1.
22. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 2.
23. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 3.
24. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 4.
25. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 5.
26. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 6.
27. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 7.
28. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of a compound of Claim 8.
29. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amont of a compound of Claim 9.
30. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 10.
31. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 11.
32. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 12.
33. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 13.
34. A pharmaceutical composition consisting eseentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 14.
35. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 15.
36. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 16.
37. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 17.
38. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 18.
39. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 19.
40. A pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and an effective amount of the compound of Claim 20.
41. A process for preparing a compound of Claim 1 which comprises:
(1) reacting a carboxylic acid of the formula (XXVII) where Ar is defined in Claim 1 with methyl chloroformate followed by sodium azide to prepare an acylazide for the formula (XXIX);

(2) reacting a compound of formula (XXIX) with glycidyl azide to prepare an oxazolidinone of the formula (I) Ar where B is N3, and optionally (3) reacting a compound of formula I) from step (2) with hydrogen to prepare the corresponding compound where B is NH2; and optionally (4) reacting a compound as prepared in step (3) with acetyl chloride to prepare a corresponding compound where B is
CA000607006A 1988-07-29 1989-07-28 Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents Expired - Fee Related CA1337526C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US225,809 1988-07-29
US07/225,809 US4948801A (en) 1988-07-29 1988-07-29 Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents

Publications (1)

Publication Number Publication Date
CA1337526C true CA1337526C (en) 1995-11-07

Family

ID=22846337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000607006A Expired - Fee Related CA1337526C (en) 1988-07-29 1989-07-28 Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents

Country Status (16)

Country Link
US (1) US4948801A (en)
EP (1) EP0352781A3 (en)
JP (1) JP2899319B2 (en)
KR (1) KR910002817A (en)
AU (1) AU622465B2 (en)
CA (1) CA1337526C (en)
DK (1) DK374389A (en)
FI (1) FI893618A (en)
HU (1) HUT58062A (en)
IE (1) IE892438L (en)
IL (1) IL91129A0 (en)
MY (1) MY104096A (en)
NO (1) NO893076L (en)
NZ (1) NZ230108A (en)
PT (1) PT91315A (en)
ZA (1) ZA895778B (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320730C (en) * 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
JP3176626B2 (en) * 1991-11-01 2001-06-18 ファルマシア・アンド・アップジョン・カンパニー Substituted aryl- and heteroarylphenyloxazolidinones useful as antimicrobial agents
SK283420B6 (en) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
NZ257031A (en) * 1992-12-08 1996-07-26 Upjohn Co Tropone substituted phenyloxazolidinone derivatives and anti-bacterial medicaments thereof
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA &amp; UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
US5668286A (en) * 1994-03-15 1997-09-16 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
JPH0873455A (en) * 1994-03-15 1996-03-19 Upjohn Co:The Oxazolidinone derivative and medicine composition containingit as effective component
DE4425612A1 (en) * 1994-07-20 1996-04-04 Bayer Ag 6-membered nitrogen-containing heteroaryl oxazolidinones
DE4425613A1 (en) * 1994-07-20 1996-01-25 Bayer Ag 5-membered heteroaryl oxazolidinones
PT788498E (en) * 1994-10-26 2002-02-28 Upjohn Co ANTIMICROBIAL COMPOUNDS OF PHENYLXAZOLIDINONE
DK0710657T3 (en) 1994-11-02 1999-05-25 Merck Patent Gmbh Adhesion receptor antagonists
MX9703543A (en) * 1994-11-15 1997-08-30 Upjohn Co Bicyclic oxazine and thiazine oxazolidinone antibacterials.
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
DK0807112T3 (en) * 1995-02-03 2001-12-17 Upjohn Co Antimicrobial heteroaromatic ring-substituted phenyloxazolidinone
WO1996035691A1 (en) * 1995-05-11 1996-11-14 Pharmacia & Upjohn Company Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones
HUP9901979A3 (en) * 1995-09-01 2000-03-28 Upjohn Co Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings and pharmaceutical compositions containing the same
US5883093A (en) * 1995-09-12 1999-03-16 Pharmacia & Upjohn Company Phenyloxazolidinone antimicrobials
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
DE19604223A1 (en) * 1996-02-06 1997-08-07 Bayer Ag New substituted oxazolidinones
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
GB9604301D0 (en) * 1996-02-29 1996-05-01 Zeneca Ltd Chemical compounds
ES2166073T3 (en) * 1996-04-11 2002-04-01 Upjohn Co PROCEDURE TO PREPARE OXAZOLIDINONES.
GB9609919D0 (en) 1996-05-11 1996-07-17 Zeneca Ltd Chemical compounds
DE69716925T2 (en) * 1996-08-21 2003-09-11 Upjohn Co ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTIMICROBE
NZ501412A (en) 1997-05-30 2001-11-30 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
EP0994874A1 (en) * 1997-07-11 2000-04-26 PHARMACIA &amp; UPJOHN COMPANY Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
GB9717807D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
CA2304100A1 (en) 1997-11-07 1999-05-20 Pharmacia & Upjohn Company Process to produce oxazolidinones
CA2303959A1 (en) * 1997-11-12 1999-05-20 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
US6083967A (en) * 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
AU764184B2 (en) * 1998-01-23 2003-08-14 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
US6562844B2 (en) 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
US7002020B1 (en) 1998-01-23 2006-02-21 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
EP1054874B1 (en) * 1998-02-13 2002-08-28 PHARMACIA &amp; UPJOHN COMPANY Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
ID30299A (en) * 1998-06-05 2001-11-22 Astrazeneca Ab OKSAZOLIDINON DERIVES, THE PROCESS OF MAKING IT AND THE PHARMACY COMPOSITION THAT CONTAINS IT
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
WO2000029396A1 (en) * 1998-11-17 2000-05-25 Bayer Aktiengesellschaft Novel substituted phenyloxazolidone derivatives
WO2000045177A1 (en) 1999-01-27 2000-08-03 Pharmacia & Upjohn Company Assays for modulators of elongation factor p activity
KR100333492B1 (en) * 1999-05-27 2002-04-25 박호군 Isoxazolylmethylene oxazolidinone derivatives and preparation thereof
KR100333493B1 (en) * 1999-05-27 2002-04-25 박호군 Isoxazolylcarbonyl oxaxolidinone derivatives and preparation thereof
KR20020022787A (en) 1999-07-28 2002-03-27 로렌스 티. 마이젠헬더 Oxazolidinones and Their Use as Antiinfectives
JP2003529544A (en) * 1999-09-13 2003-10-07 インサイト・ビジョン・インコーポレイテッド Topical treatment for prevention of eye infections
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
KR100731469B1 (en) * 2000-06-05 2007-06-21 동아제약주식회사 Oxazolidinone derivatives containing pyridine moiety and process for the preparation thereof
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
AU2001269370B2 (en) 2000-07-17 2005-10-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
EP1328509B1 (en) 2000-10-17 2006-03-22 Pharmacia &amp; Upjohn Company LLC Methods of producing oxazolidinone compounds
JP2004518677A (en) 2000-12-21 2004-06-24 ファルマシア・アンド・アップジョン・カンパニー Antibacterial quinolone derivatives and their use to treat bacterial infections
DE10129725A1 (en) 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
US6956040B2 (en) 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
NZ531621A (en) 2001-09-11 2005-06-24 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
AU2002339721A1 (en) * 2002-09-20 2004-04-08 Lupin Limited Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
MXPA05005651A (en) * 2002-11-28 2005-07-27 Astrazeneca Ab Oxazolidinone and / or isoxazoline derivatives as antibacterial agents.
GB0229521D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
DE10300111A1 (en) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
TW200500360A (en) * 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
AR044152A1 (en) 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
US6969726B2 (en) * 2003-06-03 2005-11-29 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US8324398B2 (en) * 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
CN100457742C (en) * 2003-06-03 2009-02-04 瑞伯-X医药品有限公司 Biaryl heterocyclic compounds and methods of making and using the same
AU2004256083B2 (en) * 2003-07-02 2007-10-11 Kyorin Pharmaceutical Co., Ltd. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
US20070185132A1 (en) * 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
EP1660465B1 (en) * 2003-07-29 2014-12-17 Melinta Therapeutics, Inc. Process for the synthesis of biaryl oxazolidinones
JP2007500707A (en) * 2003-07-29 2007-01-18 リブ−エックス ファーマシューティカルズ,インコーポレイテッド Biarylheterocyclic amines, amides and sulfur-containing compounds and methods for making and using the compounds
JP4777246B2 (en) * 2003-07-29 2011-09-21 リブ−エックス ファーマシューティカルズ,インコーポレイテッド Synthesis method of biaryl oxazolidinone
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
US7129259B2 (en) * 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (en) * 2003-12-18 2008-08-26 동아제약주식회사 Novel oxazolidinone derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same for antibiotics
JP2008508271A (en) * 2004-07-28 2008-03-21 リブ−エックス ファーマシューティカルズ,インコーポレイテッド Biaryl heterocyclic compounds and methods of making and using the compounds
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
US7291614B2 (en) * 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
ATE496914T1 (en) 2005-06-08 2011-02-15 Rib X Pharmaceuticals Inc METHOD FOR SYNTHESIS OF TRIAZOLES
DE102005045518A1 (en) * 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
DE502006009169D1 (en) 2005-10-04 2011-05-05 Bayer Schering Pharma Ag NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID
DE102005047558A1 (en) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders
DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
WO2007133803A2 (en) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
CN103980151A (en) 2006-08-09 2014-08-13 史密丝克莱恩比彻姆公司 Novel compounds as antagonists or inverse agonists at opioid receptors
AU2009228293B2 (en) 2008-03-26 2012-11-08 Tennor Therapeutics (Suzhou) Limited Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
CN102131811A (en) 2008-06-24 2011-07-20 财团法人乙卯研究所 Oxazolidinone derivative having fused ring
KR101023174B1 (en) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 Novel Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and Pharmaceutical Compositions thereof
CN106220621B (en) 2008-10-10 2019-06-11 默沙东公司 Prepare the method for oxazolidinones and the composition containing oxazolidinones
KR101739923B1 (en) 2009-02-03 2017-05-25 머크 샤프 앤드 돔 코포레이션 Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
CA2816515A1 (en) 2010-11-03 2012-05-10 Wockhardt Limited Process for the preparation of phosphoric acid mono-(1-{4-[(s)-5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2,6-difluorophenyl}-4-methoxymethylpiperidin-4-yl) ester
CN103896963B (en) * 2012-12-26 2017-06-09 中国科学院上海药物研究所 Ben Bing Evil Qin oxazolidinone compounds and its production and use
ITRM20130155A1 (en) * 2013-03-15 2014-09-16 I E Me S T Istituto Euro Mediter Raneo Di Scien NEW 1,2,4-OXADIAZOLIC ACTIVE COMPOUNDS AGAINST GRAM-POSITIVE PATHOGENS.
US9862710B2 (en) 2013-03-15 2018-01-09 Istituto Euro Mediterraneo Di Scienza E Tecnologia 1,2,4-oxadiazol compounds active against gram-positive pathogens
CN105209458B (en) * 2013-03-15 2019-01-04 米兰比可卡大学 It is novel that there is the active 1,2,4- oxadiazole compound of resisting gram-positive pathogen
CN103965183B (en) * 2014-03-17 2017-05-03 上海应用技术学院 Fluorine-containingoxazolidinonecompound as well as preparation method and application thereof
WO2015173664A1 (en) 2014-05-14 2015-11-19 Wockhardt Limited Process for the preparation of (5s)-n-{3-[3,5-difluoro-4-(4-hydroxy-4-methoxymethyl-piperidin-1-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
CN106083994B (en) * 2016-04-18 2019-12-06 南京曼杰生物科技有限公司 Substituted oxazolidinone water-soluble derivatives and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010873A (en) * 1956-10-03 1961-11-28 Maggioni & C Spa alpha-[(p-chlorophenyl)-alpha-phenyl]-4-pyridyl carbinol as a potentiating agent
FR2356422A1 (en) * 1976-03-01 1978-01-27 Delalande Sa NEW HYDROXYMETHYL-5 OXAZOLIDINONE-2, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS
FR2500450A1 (en) * 1981-02-25 1982-08-27 Delalande Sa NOVEL AMINOMETHYL-5-OXAZOLIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE THEREOF
ES8506659A1 (en) * 1983-06-07 1985-08-01 Du Pont Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents.
CA1260948A (en) * 1984-12-05 1989-09-26 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
CA1320730C (en) * 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
CA1317594C (en) * 1987-10-21 1993-05-11 Chung-Ho Park Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents

Also Published As

Publication number Publication date
JP2899319B2 (en) 1999-06-02
KR910002817A (en) 1991-02-26
MY104096A (en) 1993-11-30
DK374389D0 (en) 1989-07-28
AU622465B2 (en) 1992-04-09
EP0352781A2 (en) 1990-01-31
FI893618A0 (en) 1989-07-28
NO893076D0 (en) 1989-07-28
AU3911589A (en) 1990-02-01
ZA895778B (en) 1991-03-27
HUT58062A (en) 1992-01-28
NO893076L (en) 1990-01-30
IE892438L (en) 1990-01-29
FI893618A (en) 1990-01-30
EP0352781A3 (en) 1990-07-11
PT91315A (en) 1990-02-08
IL91129A0 (en) 1990-03-19
DK374389A (en) 1990-01-30
US4948801A (en) 1990-08-14
JPH02124877A (en) 1990-05-14
NZ230108A (en) 1991-10-25

Similar Documents

Publication Publication Date Title
CA1337526C (en) Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5043443A (en) Aminomethyloxooxazolidinyl arylbenzene derivatives
CA1322001C (en) Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
CA1320730C (en) Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US4921869A (en) Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
EP0316594B1 (en) Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
AU611627B2 (en) Aminoethyl oxazolidinyl benzene derivatives useful as antibacterial agents
US4977173A (en) Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
CA1254213A (en) Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents
US4965268A (en) Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US5130316A (en) Aminomethyloxooxazlidinyl arylbenzene derivatives useful as antibacterial agents
RU2417223C2 (en) Oxazolidinone derivatives, method for preparing thereof (versions) and based pharmaceutical composition
US4942183A (en) Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
JP2005538937A (en) New florfenicol antibiotics
WO2010074776A2 (en) Compounds for the treatment of cancer
US5036092A (en) Aminomethyl oxooxazolidinyl azacycloalkylbenzene derivatives useful as antibacterial agents
US4985429A (en) Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
Barbachyn et al. Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents 2. Modification of the phenyl ring—the potentiating effect of fluorine substitution on in vivo activity
US5032605A (en) Aminomethyl oxooxazolidinyl oxa or thia cycloalkylbenzene derivatives useful as antibacterial agents
US5039690A (en) Aminomethyl oxooxazolidinyl oxa or thia cycloalkylbenzene derivatives useful as antibacterial agents
US5036093A (en) Aminomethyl oxooxazolidinyl azacycloalkylbenzene derivatives useful as antibacterial agents
US6365612B2 (en) Benzosultam oxazolidinone antibacterial agents
US7435751B2 (en) 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents
WO2009077485A2 (en) 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents

Legal Events

Date Code Title Description
MKLA Lapsed